neuroscience speakers innovation forum · 2018/10/05 · neuroscience innovation forum for...

www.sachsforum.com

NEUROSCIENCE INNOVATION FORUM

FOR BD&L AND INVESTMENTIN THERAPEUTICS AND TECHNOLOGY

7TH JANUARY 2018

MARINE’S MEMORIAL CLUB

SAN FRANCISCO, USA

CONFERENCE GUIDE

www.sachsforum.com

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

www.sachsforum.com

SACHS ASSOCIATES ARE DELIGHTED TO WELCOME YOU TO THE:

NEUROSCIENCEINNOVATIONFORUMFOR BD&L AND INVESTMENTIN THERAPEUTICS AND TECHNOLOGY

7TH JANUARY 2018MARINE’S MEMORIAL CLUBSAN FRANCISCO, USA

GENERAL INFORMATION

The registration desk will be open from 7.30 am on January 7th although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

Networking at the summit is facilitated by our online One-2-One meeting system, which is available to all participants.

REQUEST FOR PRESENTATIONS

Please use the agenda to mark off presentations that you are interested in and email your request to [email protected] after the conference. We will endeavor to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter.

Please note that we DO NOT have copies of the slides that are shown during the conference.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

www.sachsforum.com

NEUROSCIENCE INNOVATION FORUM FOR BD&L AND INVESTMENT IN THERAPEUTICS AND TECHNOLOGY

Sachs Associates are delighted to welcome you to the Neuroscience Innovation Forum. Building on the success of our 2nd Annual Neuroscience BioPartnering & Investment Forum we are pleased to announce the Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology to take place at Marines’ Memorial Club, San Francisco on the 7th of January 2018, a day before the JP Morgan meeting.

The program will cover BioPartnering for CNS, with industry keynotes and panels on AD, PD, Neuropsychiatry and Pain Management. Moreover, there are panels on innovation in NeuroTech covering banking, device, diagnostics and software.

The target audience are buy and sell side analysts from investment banks and funds and partnering executives from pharma and medtech companies. We anticipate around 200+ delegates and 20+ company presentations by established and emerging companies. There are numerous networking opportunities available via an online one-to-one meeting system with dedicated meeting facilities to make the event more transactional.

www.sachsforum.com

EVENTS DIARY

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Silvia Kar on [email protected]

11TH ANNUALEUROPEAN LIFE SCIENCES CEO FORUM & EXHIBITION

FOR PARTNERING AND INVESTING IN BIOTECH & PHARMA INDUSTRY

26TH – 27TH FEBRUARY 2018 • HILTON ZURICH AIRPORT HOTEL • SWITZERLAND

Back for its eleventh year, this exclusive and highly transactional partnering event is a must for companies wishing to meet with their peers, engage with leading investors and forge new partnerships.

Building on the success of this year’s event, the forum will provide an excellent platform to gain insight into partnering and investment trends in the Biotech and Pharma industry. Networking at the forum is facilitated by our online One-2-One meeting system, which is available to all participants.

The conference will feature up to 80 presentations by large to mid-size pharmaceutical companies looking for strategic alliances/partners, plus 20+ short presentations by seed companies.

Do not miss out on this great opportunity to meet emerging companies, leading global investors and Big Pharma representatives!

SACHS BIOCAPITAL USA FORUM

FOR PHARMA – BIOTECH PARTNERING & INVESTMENT OPPORTUNITIES

21ST MARCH 2018 • NEW YORK ACADEMY OF SCIENCES • USA

Returning to New York in March 2018, Sachs Associates is pleased to announce the Sachs BioCapital USA forum. Building on the success of Sachs forums in Europe and the USA, we decided to combine the 2nd Neuroscience BioPartnering & Investment and the 5th Cancer BioPartnering & Investment forums and make one event - Sachs BioCapital USA forum (BCUSA) that will take place on the 21st of March at the at the New York Academy of science.

The BCUSA showcases biotechs with advanced therapeutics and brings them together with pharma partnering executives and institutional investors, bankers and advisers. The programme features panels on pharma-biotech dealmaking, advances in different therapeutics areas and a keynote and roundtable on investment. We anticipate up to 300 delegates and around 30 company presentations (public and private) and an emerging company track. Our online One-2-One meeting system with dedicated meeting facilities will provide numerous networking opportunities and will make event even more transactional.

4TH ANNUALIMMUNO-ONCOLOGY: BD&L & INVESTMENT FORUM1ST JUNE 2018 • WALDORF ASTORIA CHICAGO HOTEL • USA

Taking place on the first day of ASCO, the 4th Annual Immuno-Oncology: BD&L and Investment forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment.

Numerous networking opportunities available via an online one-to-one meeting system with dedicated meeting facilities to make the event more transactional.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

www.sachsforum.com


www.sachsforum.com

6TH ANNUALMEDTECH & DIGITAL HEALTH FORUM

3RD OCTOBER 2018 • CONGRESS CENTER BASEL • SWITZERLAND

This year again we will be holding our 6th MT&DH Forum one day before our 18th Annual BEF forum, on 3rd of October at the Congress Center Basel. The programme is designed to highlight the latest industry developments and showcase emerging and innovative technology companies seeking finance and partnerships. The delegates are comprised of Healthcare, MedTech, Healthcare IT and Digital Health companies as well as consultants, bankers and corporate & financial investors. We expect over 250 delegates and 25 presenting companies plus presentations by seed companies.

The forum will provide a number of networking opportunities via our online one-to-one meeting system which allows you to pre-book meetings with all the attendees with dedicated meeting facilities.

18TH ANNUALBIOTECH IN EUROPE FORUM4TH – 5TH OCTOBER 2018 • CONGRESS CENTER BASEL • SWITZERLAND

The forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. We expect over 650 delegates and over 100 presenting companies plus presentations by seed companies.

The 18th Annual BEF will be held for the fifth time in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand one-to-one meetings as well as significant exhibition space. The programme will feature number of plenary panels/workshops covering BD & Licensing in the main therapeutic areas.

The forum will provide a number of networking opportunities via our online one-to-one meeting system which allows you to pre-book meetings with all the attendees with dedicated meeting facilities. We expect more than 1500 meetings to take place throughout the 2 days.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

www.sachsforum.com


www.sachsforum.com

GB SCIENCES, INC.

ANDREA SMALL-HOWARD

Chief Science Officer

Dr. Andrea Small-Howard leverages broad biopharmaceutical industry knowledge and contacts in her current dual roles as the Chief Science Officer and member of the Board of Directors at GB Sciences, Inc. Dr. Small-Howard has more than 15 years experience studying cannabinoids and the endocannabinoid system, immunology and cancer treatments; as well as executive experience in the biopharmaceutical industry where she supervised research and development, manufacturing and quality control divisions. She took the lead in obtaining regulatory approvals from the U.S. Food and Drug Administration (“US FDA”) and multiple international regulatory agencies, and has assisted state jurisdictions in developing medical cannabis regulations.

She brings to GB Sciences a passion for advancing clinical research on medicinal applications of cannabinoid compounds in cannabis plants, clinical experience in conducting cannabinoid research, strategic vision for creating a vertically integrated biopharmaceutical pipeline, and a track record of successes in the management of biopharmaceutical companies.

Dr. Small-Howard originally received her AB from Occidental College (Magna Cum Laude, Phi Beta Kappa), in addition to receiving both an MBA (Beta Gamma Sigma) and a PhD (USC All-University Merit Fellow) in biological sciences from the University of Southern California. As a post-doctoral fellow at the Queens Medical Center in Honolulu, Hawaii, Dr. Small-Howard led a project group dedicated to the study of cannabinoids in the immune system and published two peer-reviewed papers on the subject. At the John A. Bums School of Medicine – University of Hawaii, she led a productive research team as a Research Assistant Professor.

Dr. Small-Howard has held management positions at AMDL, Inc. (a small public biotech company), where she took the lead in every stage of product development from discovery through commercialization. As Vice President of Scientific Oversight at Radient Pharmaceuticals Corp. (RPC), she provided strategic technical and regulatory oversight for global product development in multiple international business divisions. At RPC, she also played an active role in creating collaboration agreements with development partners and research institutions, and she contributed to critical licensing and distribution agreements.

For a four year term, she served on the Board of Directors for the Center for Healthcare Innovation, a nonprofit, non-partisan, and independent organization based in Chicago that is committed to serving as a catalyst for stimulating ideas, people, companies, and institutions to collaborate and achieve excellence in healthcare innovation.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

NEUROSCIENCE INNOVATION FORUMFOR BD&L AND INVESTMENT IN THERAPEUTICS AND TECHNOLOGY

ACORDA THERAPEUTICS, INC.

ANDREW HINDMAN

Chief Business Development Officer

Andrew A. Hindman joined Acorda in May 2014 as Chief Business Development Officer. Mr. Hindman is responsible for identifying and completing strategic transactions that expand the Company’s pipeline of commercial and development stage products, as well as managing the Alliance Management function for existing partnerships. His role expanded in October 2016 to include financial planning and investor relations.

Mr. Hindman has held several senior executive level positions in the biopharmaceutical industry, most recently as President, Chief Executive Officer and member of the Board of Tobira Therapeutics, a privately-held biotechnology company. At Tobira, he was responsible for developing a new corporate strategy, building new leadership and operational teams, and raising operating capital. Prior to Tobira, Mr. Hindman held senior corporate development and commercial operating positions at Nodality, Onyx Pharmaceuticals and Gilead Sciences.

www.sachsforum.com

Mr. Hindman holds a B.A. in biochemistry and economics, graduating Phi Beta Kappa, from Wesleyan University and an executive MBA from Columbia University and the University of California Berkeley, Haas School of Business.

EMERALD HEALTH THERAPEUTICS, INC.

AVTAR DHILLON

Executive Chairman

Dr. Dhillon is a life sciences entrepreneur with more than 20 years’ experience building public companies through mergers and acquisitions, leading innovation in scientific, engineering and farming enterprises, securing government grants and NGO funding (more than US$75 million to date), and building dominant IP portfolios through partnering. During his tenure as President and CEO at Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Dr. Dhillon led the turnaround of the company through restructuring and acquisitions. Under his leadership, Inovio completed financing totaling over US$250 million and sev-eral licensing deals with global pharma leaders, such as Merck, Wyeth (now Pfizer), and Roche. Before joining Inovio, he was Vice President of MDS Capital Corp. (now Lumira Capital Corp.), one of North American’s leading healthcare venture capital organizations. Dr. Dhillon practiced family medicine for over 12 years and currently sits on the board of the Cannabis Association of Canada. He has a BSc (Honours) in Human Physiology and an MD from the University of British Columbia.

SV LIFE SCIENCES

BARBARA TATE

Venture Partner

Dr. Barbara Tate is a neuroscientist who has worked in both large and small pharmaceutical companies. Prior to joining DDF, she was Vice President and Head of Biology at Rodin Therapeutics, an Atlas Venture company, where she also consulted on other portfolio companies. Prior to Rodin, Barbara was Vice President for Research at Satori Pharmaceuticals, a biotech company developing a treatment for Alzheimer’s disease. Barbara also worked at Pfizer, where she managed the neurodegenerative disease area group in Groton, CT.

Prior to working in industry, Barbara was an academic researcher at Brown Medical School and Harvard Medical School. Barbara has a BA in Biology, a PhD in Physiology, and she was a postdoctoral fellow at Harvard Medical School.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


The Dementia Discovery Fund (“DDF”) is a highly innovative new fund backed by the UK Government, Alzheimer’s Research UK and seven of the world’s leading pharmaceutical and biotech companies. The DDF is funding the discovery and development of new disease-modifying treatments for Alzheimer’s and other forms of dementia with the intent to dramatically improve the quality of life for the growing number of dementia sufferers and their families.

www.sachsforum.com

EXCELLENTIA GLOBAL PARTNERS

BETH JACOBS

Managing Partner

Beth Jacobs currently serves as Managing Partner of Excellentia Global Partners, a global life sciences investment bank, founded in 2008. Excellentia Global Partners works closely with early stage biotech and medical device companies, raising capital and enabling critical licensing and partnering with Big Pharma companies. Prior to establishing Excellentia Global Partners, Beth was a General Partner at Bio-IB, a life science-focused investment bank in New York.

Beth has served in senior executive roles in her twenty five years of experience in both investment banking and in the corporate sector. Prior to 2003, Beth served as Senior Vice President for Laureate Education (NASDAQ: LAUR), a $3 billion market cap company in the education sector. She worked across all business units in a corporate development role, with a distinct focus on identifying and executing on opportunities in China. Beth was Managing Director and Co-Head of Global Capital Markets at ING Barings, shortly after their acquisition of Furman Selz LLC, where she founded and led its international institutional equity group for over 9 years. She started her career at Prudential Securities where she founded the international institutional equity business, and later headed the same product execution group at both Morgan Stanley and Lehman Brothers.

She currently serves on the Board of Directors of EF Foundation, a global educational services company based in Stockholm and Cambridge, Mass, the Supervisory Board of Genomic Vision (GV listed on Euronext Exchange /Paris in DNA analysis), founding Global Ambassador for Susan G. Komen for the Cure, Board member for the Harvard Kennedy School of Government Women’s Leadership Board, Director of the William J. von Liebig Foundation, Board of Governors of the New York Academy of Sciences where she serves as Chair of the Investment Committee, Governance and Executive Committees. Previously, Beth served for 7 years as the Vice Chairman of the Friends of the Budapest Festival Orchestra.

Beth received an MBA in international finance from American University in Washington, DC in conjunction with the School of Foreign Service, and a BA, cum laude, from Boston College. She also studied at Centre d’Etudes Internationale in Geneva, Switzerland. Beth is fluent in French.

THE MICHAEL J. FOX FOUNDATION

BRIAN FISKE

SVP, Research Programs

Brian joined The Michael J. Fox Foundation for Parkinson’s Disease in 2004. In his current role as Senior Vice President, Research Programs, Brian co-manages a team of professionals who stay closely linked to the Parkinson’s community in order to develop an aggressive and innovative agenda for accelerating research and drug development for Parkinson’s disease. This ensures that MJFF priorities reflect and best serve the ultimate needs of patients. Brian regularly meets with academic and industry scientists around the world to identify promising research and drug development challenges needing Foundation support. He currently oversees MJFF’s strategy for enabling the development of disease-modifying and symptomatic therapies for Parkinson’s patients.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


Dr. Fiske earned an undergraduate degree in biology from Texas A&M University and a PhD in Neuroscience from the University of Virginia. After completing postdoctoral research at Columbia University, Brian spent several years as an editor at the scientific journal, Nature Neuroscience. He brings his broad experience and knowledge to the Foundation to help bring new treatments to people with Parkinson’s.

www.sachsforum.com

PJT PARTNERS

BRUCE LEUCHTER

Managing Director

Dr. Bruce Leuchter is a Managing Director at PJT Partners where he provides M&A and capital markets advisory services to companies in the life science industry with a focus on the biotechnology sector. Dr. Leuchter is a physician by training and Neuropsychiatrist by specialty. He completed residency training in Neurology and Psychiatry at New York Presbyterian Hospital and Weill Cornell Medical College and is a Dipolmate of the American Board of Psychiatry and Neurology. Dr. Leuchter served as Director of Clinical Neuropsychiatry at Weill Cornell Medical College and maintains a faculty appointment of Clinical Assistant Professor of Psychiatry. His financial services experience, prior to joining PJT Partners, includes roles in equity research and investment banking at Goldman Sachs and Credit Suisse, respectively. Given his background in neuroscience, he frequently ad-vises companies developing technologies for diseases of the brain and nervous system. Dr. Leuchter co-founded Click Therapeutics, a digital medicine company which engineers, validates and commercializes digital therapeutics across disease areas with a focus on neuropsychiatry. He serves as a member of the Scientific Advisory Committee for the Daedelus Fund for Innovation at Weill Cornell Medical College, and on the Leadership Council of the Life Science Institute at the University of Michigan.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

ORYZON GENOMICS SA

CARLOS BUESA

Chief Executive Officer

Dr Buesa holds a PhD in Biochemistry (Molecular Biology) from the University of Barcelona. He was EU post-doctoral fellow in the Faculty of Medicine at the University of Ghent in Belgium and later Senior Investigator at the Flemish Institute of Biotechnology (VIB). In 1997, he was Group Leader in the Signal Transduction Group of the UB. In 2000, he founded Oryzon Genomics and in 2002 leaved the Academy to focus exclusively in its tasks as CEO. Later he has also taken the executive education programme (PADE) at the IESE Business School in Barcelona and several other additional educational programs in BD and finances.

Under his leadership the company became a pioneer in epigenetic drugs and after a transforming partnering deal in 2014 with Roche, licensing its anti-tumoral ORY-1001 in a deal of +$500 M, Dr Buesa leaded the company public listing in 2015 in Madrid Stock exchange in Spain securing 16,5M in equity ($19M) complemented with 15.5M ($17M) of non-senior, non-convertible debt. In 2016, Oryzon was selected as one of the 3 Finalists in healthcare for the 7th Annual Most Innovative EU Biotech SME Award. In 1Q2017 he leaded a successful 18.2M€ Pipes ($20m) offering that included institutional investors specialized in healthcare and life sciences from the US, Spain and rest of Europe. The company has a second molecule ORY-2001 in Phase II in MS and AD

Dr. Buesa maintains an intense presence in the US Biotech-biopharma circuit, visiting frequently the sectoral hubs like Boston and San Francisco but also relevant cities such as New York City, Chicago or Miami. He has been presenting the Company at Investment Bank Health Care Conferences like Jefferies, Stifel, JMP Securities, Roadman Renshaw or events like BioCEO–NY or BioPharm America and many others and also to more pure scientific Conferences like CTAD, AAIC, ASH, AAN and others.


www.sachsforum.com

TILRAY

CATHERINE JACOBSON

Clinical Research Director

Catherine identifies opportunities for clinical research partnerships that fulfill Tilray’s goal of advancing knowledge of cannabinoid science by partnering with physicians and medical institutions to generate data that will inform best treatment practices. This data includes information on appropriate dosages, potential adverse effects, and other considerations important to patient populations given the particular symptoms and natural history of each disease.

Director of Research Investment for The Epilepsy Foundation

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

Prior to joining Privateer Holdings, Catherine led a venture philanthropic fund addressing the lack of adequate drugs and devices to treat pediatric epilepsy. Before that, she served as a post-doctoral fellow at the University of California, San Francisco where she established GW Pharmaceutical’s Expanded Access Investigational New Drug Application (IND) for Epidiolex for the treatment of children with severe medically refractory epilepsy. Previously, she also served as a post-doctoral fellow at Stanford University, where she conducted the first published account of the parental use of cannabis to treat severe pediatric epilepsy.

University of Colorado, Boulder: BA, Psychology

Oregon Health and Science University School of Medicine: PhD, Cell Biology, Neuroscience

Oregon Health and Science University School of Medicine: PhD, Cell Biology, Neuroscience

NOVARTIS PHARMA AG

CHARLES BAILEY

Head of Search & Evaluation, Neurosciences, Global BD&L

Charlie Bailey has over 15 years of business development experience, including transactions, search and evaluation and alliance management. He has worked with the Neuroscience Franchise at Novartis since 2013, working on major deals with GSK, Amgen and the acquisition of Spinifex Pharmaceuticals.

Charlie joined Novartis in 2011 and was previously responsible for licensing and M&A in Novartis Molecular Diagnostics. Prior to that he led R&D out-licensing activities in Roche Partnering and completed several oncology licensing deals, in roles at Roche and Mundi-pharma International.


STANFORD UNIVERSITY

CHRIS BENNETT

Instructor, Department of Psychiatry, Stanford University

Chris Bennett is a practicing psychiatrist and Instructor in the department of psychiatry at Stanford University. He devotes the majority of his time to pre-clincal neuroscience research focused on the fundamental biology of glial cells. He is interested in using fundamental cellular and molecular discoveries about glia to design better treatments for psychiatric illness.

www.sachsforum.com

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

FORTRESS BIOTECH, INC.

DANNY TALATI

Director, New Business Development

Danny is a Director of Business Development at Fortress Biotech, a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through its subsidiary companies, also known as Fortress Companies. At Fortress, Danny focuses on opportunities in neuroscience and neurology. Prior to Fortress, Danny worked as a Consultant at Torreya Insights, assisting companies in all aspects of business development transactions. Additionally, Danny worked at Lilly for a decade, primarily as a Neuroscience and Neurology Medical Science Liaison. Danny holds a Doctor of Pharmacy degree from Northeastern University and an MBA from London Business School.

MERCK & CO.

DARRYLE SCHOEPP

VP Neuroscience Research

Dr. Schoepp is responsible for Neuroscience discovery strategy and execution at Merck. He joined Merck Research Laboratories in 2007. During his tenure at Merck the Neuroscience group has successfully developed and launched Suvorexant (Belsomra) for insomnia and established an industry leading innovative Neuroscience pipeline for Alzheimer’s disease, Parkinson’s disease, pain/migraine, and schizophrenia.

Prior to joining Merck, Dr. Schoepp was a drug discovery scientist at Eli Lilly for 20 years, where from 2004 – 2007 he served as vice president of neuroscience research responsible for the company’s neuroscience strategy and pipeline.

As a scientist, he is recognized for having made major contributions in the investigation of the excitatory amino acid neurotransmitter glutamate in disease pathophysiology, pharmacology and therapeutics. Dr. Schoepp’s honors include the 2002 Pharmacia / ASPET Award for Experimental Therapeutics for his research on the experimental therapeutics of glutamate receptors modulators in CNS disorders, and 2007 Ray Fuller / ASPET Lecturer in Neurosciences in recognition of translational pharmacology work in the glutamate field. He has organized and/or participated in numerous international meetings and symposium, published over 200 papers and reviews, and is an inventor of 15 US patents.

Dr. Schoepp received his bachelor’s degree in Pharmacy from North Dakota State University and his doctoral degree in Pharmacology and Toxicology from West Virginia University.


ACADIA PHARMACEUTICALS, INC.

DAMIEN MCDEVITT

Senior Vice President, Corporate Development

Dr. Damien McDevitt joined ACADIA Pharmaceuticals in November 2017 as SVP Corporate Development. Prior to that, Damien spent two decades at GlaxoSmithKline plc, where he was at the forefront of the R&D externalization efforts, and involved in more than 70 global business development transactions spanning a variety of therapeutic areas, including neuroscience. Most recently, he was Vice President, Head of Business Development for R&D Extended Therapy Areas, head of Worldwide Business Development Asia, and head of the company’s R&D West Coast Satellite. Prior to that, Damien held positions with increasing responsibility within Worldwide Business Development, GSK Ventures and Anti-Infectives Discovery. He is a member of the Southern California BIOCOM board and a member of its capital development committee. Dr. McDevitt attended Trinity College in Dublin, Ireland, where he earned his Ph.D. and his undergrad-uate degree, both in Microbiology. Damien is an author of 70 scientific publications and published patents.

www.sachsforum.com

CLICK THERAPEUTICS, INC.

DAVID KLEIN


WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

Prior to joining Elsevier, Cassak worked for nearly 20 years at Windhover Information Inc., a company he founded with his partner, Roger Longman, which spun out the publications business of The Wilkerson Group, a leading management consulting firm at the time. Long known for publishing IN VIVO, widely recognized as the premier provider of business intelligence in the health care industry, Windhover launched a number of other successful publications, including START-UP: Emerging Medical Ventures, and The RPM Report: Regulation • Policy • Market Access. In 2004, Windhover acquired Medtech Insight, Inc., which published the MEDTECH INSIGHT: Medical Technology Market Intelligence newsletter. While at Windhover/EBI, David also organized and produced numerous conferences around the world, including the Investment in Innovation (In3) medical device partnering conference series, as well as such pharma-focused conferences as Pharmaceutical Strategic Alliances, Euro-Biotech and BIO-Windhover. In 2008, Windhover was acquired by Elsevier, which formed Elsevier Business Intelligence, combining the products of Windhover and F-D-C Reports, publishers of The Gray Sheet and The Pink Sheet, among other industry newsletters.

David Benshoof Klein is a healthcare investor and entrepreneur with over 15 years life science industry experience; he has played key roles in founding, financing and operating more than 10 life science companies. In 2012, Mr. Klein co-founded Click Therapeutics which develops and commercializes software as medical treatments: Digital Therapeutics™. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depres-sive Disorder in adults. He formerly served as Managing Director at Opus Point Partners, senior consultant to Pfizer, and strategic advisor to numerous publicly traded and privately held life science companies. Mr. Klein holds a B.A. from Brandeis University and has been a guest lecturer at Columbia University’s Biotechnology Program. A native New Yorker, Mr. Klein is an avid art enthusiast and is co-founder and owner of Klein Sun Gallery, America’s leading Chinese contemporary art gallery with locations in New York’s Chelsea art district and Beijing, China.


INNOVATION IN MEDTECH, LLC

DAVID CASSAK

Editor-in-Chief

David Cassak has more than 30 years of experience in the health care industry. Prior to co-founding Innovation In Medtech, LLC, he served as Vice President, Content, and Managing Director, Medical Devices for Elsevier Business Intelligence, a Reed Elsevier Company, including the publications The Gray Sheet and The Pink Sheet. He also wrote extensively on the medical device industry for Windhover Information’s monthly publications, IN VIVO, START-UP, and MEDTECH INSIGHT. He is a frequent speaker before various companies and trade groups within the medical device industry.

www.sachsforum.com

ALLERGAN, INC.

DON FRAIL

SVP, Research, External Science, and Non-clinical and Translational Sciences

Don joined Allergan in 2014 and leads the Research, Non-clinical (e.g. Tox, ADME), and Clinical Pharmacology efforts for the organization and the External Science & Innovation efforts that partner with Business Development to evaluate and implement partnerships, licensing, and acquisitions. Recent neuroscience deals include the acquisiton of Naurex and partnerships with Aptinyx, Heptares and Lysosomal Therapeutics, With over twenty years of pharmaceutical and academia research and management experience Don has been involved in a variety of pre-clinical drug discovery and Ph1/Ph2 clinical research areas and environments, including the entry of more than 25 compounds into development. Previous roles included heading the Emerging Innovations Unit at AstraZeneca, CSO of the Indications Discovery Unit and Saint Louis site head at Pfizer, and the CNS Discovery organization at Pharmacia.

PROMIS™ NEUROSCIENCES, INC.

EUGENE WILLIAMS

Executive Chairman

He is currently the Executive Chairman and Co-Founder of ProMIS Neurosciences, a publicly traded company focused on neurodegenerative diseases. ProMIS has a proprietary science platform that enables the rational drug design of antibodies which selectively target the toxic oligomer variant of proteins that mis-fold and drive diseases like Alzheimer’s and ALS. ProMIS has validated assets targeting the oligomer forms of amyloid beta, TDP43, and SOD1, with discovery work ongoing identifying targets for alpha-synuclein and tau.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

Prior to ProMIS, Mr. Williams was the CEO and Co-Founder of Dart Therapeutics (now called Akashi), an Orphan Disease drug development company focused on Duchenne Muscular Dystrophy. DART pioneered a novel business model – it was funded entirely by equity investments from patient foundations. Mr. Williams was an SVP at Genzyme for nearly 10 years, with senior roles integrating commercialization, drug development, and deal making. He has also been a successful entrepreneur in healthcare services. He was a Co-founder and director of Adheris, which became the largest company in the patient adherence area. He started his career as a strategy consultant at Bain and Corporate Decisions Inc. (a Bain Spin off, now part of Oliver Wyman), where he was Co-Head of the Healthcare practice and spent extensive time on projects related to both speeding and improving the drug development process and commercialization strategies. Mr. Williams holds a B.A. from Harvard University and an M.B.A. from Harvard Business School.


BIONOMICS LTD.

DEBORAH RATHJEN

Chief Executive Officer & Managing Director

Dr Rathjen joined Bionomics in 2000 from Peptech Limited, where she was general manager of business development and licensing. Dr Rathjen was a co-inventor of Peptech’s TNF technology and leader of the company’s successful defence of its key TNF patents against a legal challenge by BASF. Dr Rathjen has significant experience in company building and financing, mergers and acquisitions, therapeutic product research and development, business development, licensing and commercialisation. Dr Rathjen has been recognised both in Australia and internationally through awards and honours including the 2004 AusBiotech President’s Medal, 2006 Flinders University Distinguished Alumni Award, 2009 BioSingapore Asia Pacific Biotechnology Woman Entrepreneur of the Year, 2009 Regional Finalist Ernst & Young, Young Entrepreneur of the Year, and 2014 Woman Executive of the Year BioPharm Industry Awards. In 2015 Dr Rathjen was included in the Top 50 most influential Australia business women by The Australian newspaper.

www.sachsforum.com


JOHNSON & JOHNSON INNOVATION

GUY SEABROOK

Vice President & Global Lead, Neuroscience External Innovation

Guy joined Janssen Pharmaceutical Companies of Johnson & Johnson in 2012 and is currently based at the J&J Innovation Center, South San Francisco, California. His role as the Global Lead for Neuroscience External Innovation is to create and implement the external innovation plan to deliver the Neuroscience Therapeutic Area R&D Strategy. He has 27 years of drug discovery experience that includes preclinical research on marketed products and candidates in clinical development. Previously, Guy was part of Eli Lilly’s Global External Research & Development organization where he led the GER&D team for the Lilly Bio-Medicines Business Unit. Formerly, at Merck & Co, Guy was the Head of the West Point Department of Alzheimer’s disease Research. He graduated with a PhD in Zoology from the University of Nottingham UK (1987), and completed his postdoctoral research at the University of Miami School of Medicine USA. He is a member of the British Pharmacological Society, The Physiological Society UK, and Biophysical Society, and has published over 90 peer reviewed papers and patent filings in the field.

SANOFI

ISAAC VEINBERGS

Head of External Innovation, NeurosciencesW

ELC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

Dr. Isaac Veinbergs is Head Of External Innovation for the Neurosciences Therapeutic Area. Isaac’s main area of focus is leveraging healthcare innovation in order to evolve and enhance Sanofi’s Multiple Sclerosis, Neurodegeneration and CNS Rare disease pipeline. This is accomplished via the cultivating of relationships and bringing forward innovative external opportunities from academic institutions, biotech & pharma companies, non-profit organizations and the investment community. Prior to joining Sanofi, Isaac was Head of Research Operations and Business Development at Brains On-Line, where he managed BOL’s research project portfolio, consisting of Industry and academically funded contract research projects. Before transitioning to the partnering side of healthcare, Isaac spent over 15 years as a scientist/manager. While at Elan, Amgen, FoldRx, and Acadia Pharmaceuticals Isaac held roles of increasing responsibility worked on small molecule and biologics approaches for discovery through PH3 stage programs. His research and leadership contributed to multiple INDs and NDAs. Isaac has co-authored multiple peer-reviewed papers that have garnered nearly 3000 citations. He has a Ph.D. in Molecular Pathology from University of California, San Diego School of Medicine.

GINGER JOHNSON


Ginger is CEO and CNS Practice Lead for Defined Health, where she manages core opportunity assessments and strategic consulting projects. Her background spans both the science and business of healthcare, ranging from basic scientific research to private equity investment and corporate development. Ginger was Vice President, Corporate Development at Skila (an e-Health company), and the Director of Life Science Research at Chase Capital Partners private equity firm (now JP Morgan Partners). Ginger was Associate Director of the Center for Biotechnology at Northwestern University and spent eight years in basic and applied scientific research, primarily in the field of Alzheimer’s Disease, at the National Institute of Mental Health. Ginger holds BS in Molecular Biology from the University of Tennessee and a Ph.D. in Genetics from the George Washington University.

DEFINED HEALTH, A CELLO HEALTH BUSINESS

www.sachsforum.com

5AM VENTURES

JAMIL BEG

Principal

Jamil M. Beg joined 5AM Ventures in 2017 as a Principal. Prior to 5AM, Mr. Beg was at Sage Therapeutics (NASDAQ: SAGE) where he contributed to building the company through corporate development & strategy, medical affairs, health economics & outcomes research and commercialization roles. Prior to Sage, Mr. Beg was an investment professional at Quaker Partners and an operator in several of the firm’s portfolio companies, including EKR Therapeutics (acquired by Cornerstone Therapeutics), Transave Inhalation Therapeutics (acquired by Insmed), NuPathe (NASDAQ: PATH, acquired by Teva) and Cempra (NASDAQ: CEMP). Mr. Beg started his career at Cambridge Pharma Consultancy (acquired by IMS Health) with a focus on pricing, market access and health economics outcomes research strategies for the biopharma industry. Mr. Beg earned his B.S.E. in Bioengineering and Master of Biotechnology degrees from the University of Pennsylvania. He earned his M.B.A. in Healthcare Management and Entrepreneurial Management from The Wharton School of the University of Pennsylvania where he was a recipient of the Henry J. Kaiser Family Foundation Merit Award. Mr. Beg is based in the Boston, MA office.

OPPENHEIMER & CO., INC.

JAY OLSON

Analyst

Jay Olson is a Sell Side Analyst covering a range of SMID to Large Cap Biotechnology companies at Oppenheimer. Prior to joining Oppenheimer, Jay covered SMID-Cap names and worked on the Large Cap Pharmaceuticals team at Goldman Sachs for 4 years after 4 years on the #1 II-ranked Large Cap Global Pharmaceuticals team at Sanford Bernstein. Prior to Wall Street, Jay spent 18 years in the pharmaceutical industry, working mostly for Pfizer in finance, marketing and business development. Jay received an M.B.A. in Finance and an M.S. in Chemical Engineering both from MIT, and a B.S. in Chemical Engineering from Tufts University.

ELI LILLY & CO.

JENNIFER LAIRD

Senior Director, Search & Evaluation

Jennifer Laird, Ph.D., D.Sc. is Senior Director, Search & Evaluation at Eli Lilly and Company, based at Lilly’s European Headquarters near London. The Search & Evaluation team complements Lilly’s internal R&D efforts by evaluating and in-licensing assets and technologies and by collaborating with external partners to advance molecules through discovery and development. Dr. Laird joined Lilly in 2012; prior to that, she spent 10 years at AstraZeneca as Executive Director heading the Translational Science department in Neuroscience and Project Director leading preclinical and early development projects. Dr. Laird received doctorates from Bristol University and University of Alicante, Spain, serves as an Editorial Board member of Neuropharmacology and European Journal of Pain and holds an honorary appointment as Professor of Pharmacology at McGill University, Canada.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com

BIOGEN

JESSE CEDARBAUM

VP, Early Clinical Development

Dr. Cedarbaum obtained his medical degree from Yale Medical School, where he is currently Professor (Adjunct) of Psychiatry. He trained in Internal Medicine at the University of Chicago and did his Neurology residency at New York Hospital-Cornell Medical Center. After residency, Dr. Cedarbaum joined the Cornell faculty and became a Staff Physician at Burke, leading the Parkinson and Movement Disorders program at Burke and New York Hospital, working with Dr. Fletcher McDowell, from 1983-1990.

After leaving Burke and Cornell, Dr. Cedarbaum joined Regeneron, where he led the establishment of the clinical development function and served as Program Director and later Vice President of Clinical Affairs from 1990-2007. He subsequently held positions as Vice President of Clinical Development and Therapeutic Area Head for Alzheimer’s Disease at Elan, and as Vice President, Clinical Research and Operations at Cytokinetics. From 2012- 2013 he was Vice President, Global Clinical Development for Neuroscience at Bristol-Myers Squib, where he was responsible for late-stage programs in neurology and psychiatry. He joined Biogen in April 2014 where he is currently Vice President, Early Clinical Development, focusing on Parkinson’s disease and movement disorders.

Dr. Cedarbaum has authored or co-authored over 90 peer-reviewed scientific publications, most in the area of neurotherapeutics. He is a Fellow of both the American Academy of Neurology and the American Neurological Association. He was a founding member of and has served as a member and as Secretary of the Board of Directors of the American Society for Experimental Neurotherapeutics (ASENT), has been a member of the NINDS Parkinson’s Disease Biomarkers Identification Network (PDBIN) Committee, and the fNIH Neuroscience Biomarkers Consortium Steering Committee. Dr. Cedarbaum was the 2014-15 chair of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Private Partner Scientific Board, and in 2015-1016 chaired the Industry Scientific Advisory Board for the Michael J. Fox Foundation’s Parkinson Progression Marker Initiative (PPMI).

TAKEDA CALIFORNIA, INC.

JOHANNES GROSSE

Director, Neuroscience Alliances

Trained as a physician I started a clinical career at the prestigious neurology department of the Charité hospital at the Humboldt-University in Berlin, Germany. After several years of shifting between bench and beside I followed my scientific interests and focussed on experimental neuro-endocrinology as a research fellow at the Technical University Munich and at the Department for Molecular Neuroendocrinology at the Max-Planck-Institute of Psychiatry (Munich).

The connection of clinical neurosciences and patho-physiology with molecular and cell biology facilitated my transition to biotech (Ingenium Pharmaceuticals AG, Munich; Paradigm Therapeutics Ltd, Cambridge, UK) and eventually a big pharma company, Takeda.

Throughout my career I have held positions of increasing responsibility managing multi-disciplinary groups focussed on preclinical drug discovery and development. This includes generation of transgenic animal and cellular models for target validation and pharmacological tests and close collaboration with medicinal chemistry, ADME/toxicology groups. For several projects I have contributed to the experimental medicine plan for the transition into clinical trials.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


In my current role I initiate and manage collaborations with academic and biotech partners with a focus on co-development of pre-clinical and clinical stage assets in CNS indications.

www.sachsforum.com

PURDUE PHARMA L.P.

JOHN RENGER

Vice President, Head of Clinical Research and Translational Medicine

Dr. John Renger, V.P., leads Clinical Research and Translational Medicine at Purdue Pharma. He is responsible for overseeing end-to-end pipeline activities including preclinical toxicology, PK/DM, clinical pharmacology, statistical modeling, pharmaceutics, and early clinical development. John has had a diverse 17-year drug discovery and development background, including successfully leading a wide range of R&D teams in multiple CNS diseases areas that have led to clinical studies in chronic pain, AD, adult ADHD, schizophrenia, and chronic insomnia where he was successful in leading the team that discovered the recently approved drug, Belsomra. Dr. Renger has also recently championed the clinical development of a topically delivered gene knockdown technology in collaboration with Exicure to evaluate a novel approach in addressing novel delivery methods for gene-based medicines. He has carried out translational clinical efforts across disease targets and has worked on multiple teams that have designed clinical PET tracers for dose ranging and pharmacodynamic measures. Dr. Renger was previously Associate VP at Merck. Previously, Dr. Renger was a Merck-MIT Fellow at the Center for Learning and Memory, Massachusetts Institute of Technology. Before MIT, he worked at the Brain Science Institute, RIKEN, Wako-shi, Saitama, Japan. Dr. Renger earned his bachelor’s and doctorate degrees from the University of Iowa.

NEURORX, INC.

JONATHAN JAVITT


Dr. Jonathan Javitt serves as Founder and CEO of NeuroRx, a clinical stage pharma company that is in phase 2b/3 clinical trials with NRX-101, a first-in-class drug targeting suicidality in bipolar depression. He has a 30-year history of combining clinical understanding with expertise in medical device and drug development, health information technology, health policy, and health economics. He has played senior roles on pharmaceutical and medical device development teams for Merck, Allergan, Eyetech, Mannkind, Novartis, Pharmacia, and Pfizer.

Dr. Javitt has been a founder of 6 health informatics and analytics companies that have gone on to public exits. In each of those endeavors, he has focused on the use of leading edge technology to improve clinical care processes. He has served the administration of George W. Bush in positions related to health policy and national security. Under President Clinton, he was appointed to the White House Health Reform Task Force.

Jonathan pioneered the use of outcomes and health economic research in ophthalmologic drug and device development. He wrote the blueprint for the FDA’s Sentinel Systems program and served for 10 years as an expert consultant to the Medicare program. His experience includes regulatory expertise in FDA and CE compliance with the drug and device approval process and quality system management.

After receiving his A.B. with honors in Biochemistry from Princeton University, he completed medical training at Cornell, Harvard, the Wills Eye Hospital, and the Wilmer Ophthalmological Institute of Johns Hopkins Universitiy. He has served as Professor of Ophthalmology and Public Policy on the full-time faculties of Georgetown and Johns Hopkins Universities and remains an adjunct Professor at Johns Hopkins. In his academic career he directed and participated in more than $20 million of federally-funded research focused on outcomes of, and delivery of, health care including diseases of the eye, diabetes, and breast cancer. He authored the first book on computers in medicine in 1984 and has published more than 200 scientific works in the New England Journal of Medicine, the Journal of the American Medical Association, and numerous other peer-reviewed publications in addition to a novel. He is lead inventor on seven US patents.

In 2015 he was named Alumnus of Merit of the Harvard School of Public Health, Harvard’s top award for public health service.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com

SAMUS THERAPEUTICS, INC.

JONATHAN LEWIS

Chairman and Chief Executive Officer

Dr. Jonathan Lewis joined Samus Therapeutics in March 2016. He brings to Samus a breadth of knowledge, expertise and innovation in both the biopharmaceutical industry, medicine and science. He served in executive roles, including Chairman and Chief Executive Officer, at ZIOPHARM Oncology, taking that company from a private start-up to a publicly-listed company at the forefront of therapeutics development in immuno-oncology. He has had roles in the development and approval of several new therapeutic drugs. Dr. Lewis came to industry from academic medicine, and is a fellow of the Royal College of Surgeons, the American College of Surgeons, and the Royal Society of Medicine. He was awarded an MB.B.Ch. from University of the Witwatersrand School of Medicine, and his Ph.D. in Molecular Biology from Witwatersrand and Yale School of Medicine. He completed Surgical Residency at University of Witwatersrand, University of Cambridge and at Yale-New Haven Hospital, ultimately becoming Professor of Surgery and Medicine at the Memorial Sloan Kettering Cancer Center. Dr. Lewis has also worked as a specialist advisor and board member for multiple companies and organizations including biotechnology, government and non-profit, these include the Congressional Business Council, Hope Funds for Cancer Re-search, POPPA/NYPD, the Jackson Foundation Combat Wound Initiative Program, and the Yale Biotechnology and Pharma Society. He was Chairman of the Scientific Council, Chairman of the Board, and elected the first Life Trustee of the Hope Funds for Cancer Research, an organization dedicated to advancing research for the most difficult-to-treat cancers.

NEURALSTEM, INC.

KARL JOHE

Chief Scientific Officer

LYSOSOMAL THERAPEUTICS, INC.

KEES BEEN


Kees is CEO of Lysosomal Therapeutics Inc (LTI), a biotech company focused on probing the lysosomal enzyme system for new drug targets in neurodegenerative diseases. Specif-ically, it is leveraging the genetic link between Gaucher’s and Parkinson’s disease (PD) to develop compounds that enhance the lysosomal glucocerebrosidase enzyme activity as an entirely new and breakthrough class of agents for the personalized and disease-mod-ifying treatment in PD. The company is currently working toward an exit as part of its op-tion-to-buy collaboration with Allergan. He was formerly CEO of EnVivo Pharmaceuticals (changed to FORUM Pharmaceuticals) for eight years working on cognition drugs for Alz-heimer’s and schizophrenia. He spent four years at Biogen, where he directed the Oncology Business Unit which was sold to Idec, and was head of Business Development.

Kees holds an MBA degree from INSEAD in France and graduated from the University of Agriculture in Holland, majoring in Molecular Biology and Process Engineering. Kees likes to spend his weekend mornings flying his single-engine airplane, exploring local airports in the New England area that offer brunch menus.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


Dr. Karl K. Johe, Ph.D. Co-founded Neuralstem, Inc. in 1996 and has been its Chief Scientific Officer since 1996. Dr. Johe has over 30 years of research and laboratory experience. As a recognized expert in neural stem cell technology, he is the sole inventor of Neuralstem's granted stem cell patents and a co-inventor of Neuralstem’s granted neurogenic molecule patents. He is responsible for strategic planning and development of its therapeutic products. From 1993 to January 1997, he served as a Staff Scientist at the Laboratory of Molecular Biology of the National Institute of Neurological Disease and Stroke in Bethesda, Maryland. While holding this position, he conducted research on the isolation of neural stem cells, the elucidation of mechanisms directing cell type specification of CNS stem cells and the establishment of an in vitro model of mammalian neurogenesis. He served as the Chairman of Neuralstem, Inc. from 1996 to June 13, 2016 and served as its Director from 1996 to August 31, 2016. Dr. Johe holds a Bachelor of Arts Degree in Chemistry from the University of Kansas, a Master's Degree from the University of Kansas and a Doctorate in Biochemistry was received from the Albert Einstein College of Medicine.

www.sachsforum.com

YUMANITY THERAPEUTICS

KENNHET RHODES

Chief Scientific Officer

Dr. Rhodes is chief scientific officer of Yumanity Therapeutics, overseeing the company’s scientific platforms, translational research and drug discovery activities. Prior to Yumanity, Dr. Rhodes served as vice president, neurology discovery at Biogen, where he led a scientific organization focused on discovery and early development of novel protein and small molecule drugs for the treatment of neurodegenerative diseases. During his tenure at Biogen, Dr. Rhodes’ team delivered nine new chemical entities into preclinical development in areas such as multiple sclerosis (MS), Parkinson’s disease and Alzheimer’s disease. Dr. Rhodes and his team played a major role in the preclinical development of Aducanumab, a fully human monoclonal antibody now undergoing Phase 3 trials for the treatment of Alzheimer’s disease.

Prior to joining Biogen Idec, Dr. Rhodes spent a combined 15 years as a discovery research leader at Johnson & Johnson Pharmaceutical Research and Development, LLC (now Janssen), and Wyeth.

Dr. Rhodes earned his Ph.D. in anatomy and neurobiology at Boston University and completed postdoctoral training in systems neuroscience at the National Eye Institute, National Institutes of Health.

NEUROTECHNOLOGY INNOVATION TRANSLATOR (NIT)

KEVIN WASSERSTEIN

Founder and Chief Executive Officer

Kevin Wasserstein specializes in building medical device companies through their entire life cycle, from concept to commercialization.

Kevin is the CEO and Co-Founder of the Neurotechnology Innovations Translator (NIT), a unique translational Center in Columbus, Ohio, whose mission is to form or attract, develop, and commercialize pioneering neurotechnology companies from around the globe to improve patient well-being. With capital and service commitments of over $160M, the NIT catapults selected companies with a robust ecosystem of expertise and resources including: capital for investment, scientific and clinical innovation, engineering development, pre-clinical and clinical trialing, and manufacturing and regulatory services.

Prior to the NIT, Kevin spent over a decade as a Managing Director at Versant Ventures, where he focused on investing in and building early stage medical device companies. Kevin currently serves, or has served, in board or advisory roles with companies which include:

Acclarent (acquired: Johnson & Johnson)

Autonomic Technologies

Ebb Therapeutics

Eargo

LipoSonix (acquired: Medicis)

Lutonix (acquired: Bard)

Microfabrica

Neoguide (acquired: Intuitive Surgical)

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


Oculeve (acquired: Allergan) Respicardia

Rox Medical

Second Sight Medical (NASDAQ: EYES)

Sollis Therapeutics

St. Francis Medical (acquired: Kyphon)

The Innovation Factory

Veressa Medical

Kevin previously held numerous operating leadership roles, including marketing and business development at Guidant Corporation, business development at Heartstream, and engineering development and management at Hughes Aircraft Company.

Kevin holds both Bachelor’s and Master’s degrees in Mechanical Engineering, specializing in product design, as well as an MBA, all from Stanford University.

www.sachsforum.com

CLARUS VENTURES, LLC

KIRAN REDDY

Venture Partner

PROBIODRUG AG

KONRAD GLUND


Dr Konrad Glund has been CEO since 2006 and is the co-founder of Probiodrug AG, a bio-pharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease (AD).

Prior to setting up Probiodrug in 1997, Dr Glund founded IFB Halle GmbH. After Probiodrug sold its DP-4 diabetes assets to (OSI) Pharmaceuticals in June 2004, he joined (OSI) Prosidion, the metabolic subsidiary of (OSI) Pharmaceuticals, based in Oxford, UK, as Chief Operating Officer and Vice President of Business and Corporate Development. During this time at (OSI) Prosidion he helped integrate the diabetes program and has been responsible for several licensing deals with pharma companies. He returned to Probiodrug in 2006 as CEO.

Probiodrug AG (Euronext Amsterdam: PBD) has medical use and composition of matter patents related to the inhibition of QC and anti-pGlu-Abeta-specific monoclonal antibodies, and has, in the Company’s view a leading position in this field of research. Pobiodrug’s lead product candidate, PQ912, is a highly specific and potent inhibitor of the enzyme Glutaminyl Cyclase (QC), in phase 2 development.

Dr Glund holds a PhD in Biochemistry from the Martin-Luther-University of Halle. After completing his studies in biochemistry, he spent about 15 years as academic lecturer and conducted research in biochemistry as project and team leader at the University of Halle. Dr Glund is author or co-author of over sixty publications and is co-inventor on more than 10 patents.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

NEUROSCIENCE INNOVATION FORUM

FOR BD&L AND INVESTMENT IN THERAPEUTICS AND TECHNOLOGY

Kiran Reddy is a Venture Partner at Clarus where he focuses on new company formation and due diligence. Prior to Clarus, Kiran was at Biogen as part of the Corporate Strategy leadership team where he focused on sourcing new technologies and product opportunities to support the Company's growth via acquisitions, partnerships, and equity investments.Prior to Biogen, Kiran was an Associate Partner at Third Rock Ventures. He supported and managed various portfolio companies in addition to focusing on new company formation and new investments. He was part of the founding team and interim Chief Business Officer for SAGE Therapeutics through its IPO, and co-inventor of SAGE-547 the Phase 3 program for the rare epilepsy disorder refractory status epilepticus. Kiran was part of the team that launched Foundation Medicine, and he has served as a Board Observer for Alnara pharmaceuticals, Rhythm pharmaceuticals, and PanOptica pharmaceuticals. Before Third Rock Ventures, Kiran was a management consultant at the Lewin Group within in the biotechnology and pharmaceutical practice, and advised clients on clinical development and commercial strategy.

Kiran holds MD and MBA degrees from Georgetown University. He completed his internship in medicine and his neurology residency at Harvard/Massachusetts General Hospital and is a board certified neurologist. Kiran was previously a Howard Hughes science fellow, and has authored several peer-reviewed scientific papers in the field of neuroimmunology and neurodegenerative diseases.

www.sachsforum.com

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

LAURA CORRADINI

Deputy Global Head of BD&L, CNS

Dr. Laura Corradini received her degree in medicinal chemistry and technology, and qualified as Pharmacist at the University of Milan (Italy). Subsequently, she obtained her PhD in biotechnology at the same University.

Dr. Corradini worked for more than ten years in preclinical research at Schering-Plough Research and Development (R&D) and Pfizer R&D in the field of neuroscience and chronic pain, respectively. Since joining Boehringer Ingelheim (BI) in 2009, she has held several positions in R&D as CNS Pharmacologist for pain and ophthalmology.

Dr. Corradini currently acts as Deputy Global Head of Business Development & Licensing CNS at BI. She is responsible for search and evaluation of partnering opportunities in the therapeutic area CNS and is co-chairing BI’s cross-functional CNS Licensing Advisory Team.

The strategic partnering focus of Dr. Corradini and her team is novel therapeutic approaches to treating neuropsychiatric disorders.

BAY CITY CAPITAL, LLC

MANUEL LÓPEZ-FIGUEROA

Venture Partner

Manuel López-Figueroa, PhD, is a Venture Partner at Bay City Capital and has been with the firm since 2001. He specializes in evaluating investment opportunities with an emphasis on CNS. In addition, Dr. López is the Scientific Liaison for the Pritzker Neuropsychiatric Disorders Research Consortium, a collaborative research enterprise comprised of a group of leaders in psychiatry, neuroscience, and genetics from Stanford University, University of Michigan, Cornell University, and the Universities of California at Davis and Irvine. The consortium aims to discover the neurobiological and genetic determinants of mood disorders and schizophrenia with the goal to develop novel diagnostics and therapeutics. Dr. López is responsible for planning and directing all aspects of the consortium including strategy, R&D, legal (IP & contracts) and financial, to facilitate the commercialization of discoveries to fund additional research. Dr. López has over 15 years of experience in the field of neuro science, has won numerous awards during his academic research career, and has published extensively. He completed post-doctoral work at the University of Michigan and at the University of Copenhagen, Denmark. Dr. López received a PhD in Medicine and Surgery, and a MS in Molecular and Cell Biology from the Universities of Las Palmas and La Laguna, Spain, respectively.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com

NEXSTIM PLC

MARTIN JAMIESON

CEO, Chairman of the Board

Martin Jamieson has been the Chairman of the Board of Directors since December 2015 and CEO from April 2016. Following a marketing career in the pharmaceutical industry with Wyeth (Pfizer) and 3M, Martin joined Smith Medical - part of the FTSE 100 Smiths Group - as Director and Divisional Managing Director culminating in his final position - Managing Director Smiths Medical International. He was then appointed CEO of Rayner Group, a globally based ophthalmology company which developed the first intraocular lens. Martin has a number of Non-Executive Directorships with Light Point Medical Ltd, C-Major Ltd. and Schuco Ltd. Until December 2016 Martin was a NED at Medway NHS Hospital Foundation Trust where he was Senior Independent Director, Deputy Chair and formally Audit Chair. He also consults on international market development with Rocket Medical Plc.

BIOGEN

MICHAEL EHLERS

Executive Vice President, R&D

Michael Ehlers is Executive Vice President for Research & Development at Biogen, one of the largest and most successful biotechnology companies in the world. Dr. Ehlers grew up rural Nebraska and earned his bachelor’s degree in chemistry from Caltech. He holds M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine. Prior to joining Biogen in 2016, Dr. Ehlers was Senior Vice President for BioTherapeutics and Chief Scientific Officer for Neuroscience at Pfizer where he led the transformation of the Neuroscience and Rare Disease portfolios at Pfizer successfully bringing 22 compounds into the clinic, as well as directing global activities in biologics design, synthesis, and production, and steering a network of academic collaborations focused on immunology and oncology. Before entering his industry career in 2010, Dr. Ehlers was the George Barth Geller Professor of Neurobiology and an Investigator of the Howard Hughes Medical Institute at Duke University Medical Center, where he pioneered studies on neuronal organelles and the trafficking of neurotransmitter receptors. Dr. Ehlers’ current research focuses on the interface between neuronal cell biology, the plasticity of neural circuits, and neurological disease. At Biogen, Dr. Ehlers directs global research and development including discovery sciences, drug design, translational medicine, and clinical development, with a focus on neurological diseases. He has advanced nine novel clinical candidate compounds and oversaw the approval of SPINRAZAä (nusinersin), the first drug approved for spinal muscular atrophy. In addition, Dr. Ehlers leads business development at Biogen with responsibility over licensing and business deals, including successfully achieving Biogen’s largest pipeline deal since 2007. He is the recipient of numerous awards including the 2003 Eppendorf & Science Prize in Neurobiology, the 2007 John J. Abel Award in Pharmacology, the 2007 Society for Neuroscience Young Investigator Award, an NIMH MERIT Award, and the 2009 National Alliance for Schizophrenia and Depression Distinguished Investigator Award. He received the 2008 Breakthrough Research Award of the North Carolina Biotechnology Center given to a single scientist in North Carolina, and the 2016 Biomedical Research Award of the Massachusetts Medical Society given to a single business leader in New England. In 2013 he became the 11th recipient of the Thudichum Medal of the Biochemical Society of the United Kingdom an award inaugurated in 1974 to honor eminent scientists who have made outstanding contributions to neurochemistry and related subjects, whose recipients include two Nobel laureates.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com

VALOR MANAGEMENT S.A.

MICHAEL FARLEY

Director

Michael’s career in the international financing field spans 30 years. He founded several companies including Valor Management SA in 2002, a business advisory servicing bio industry companies and fund managers in global markets. Prior to Valor, Michael managed international life science collaboration and investment programs for the Canadian Department of Foreign Affairs and International Trade. Dr. Farley holds a PhD in the History and Philosophy of Science from the Université de Montréal (1986). His thesis is an epistomology study of life sciences in France during the Napoleonic era. Michael is fluent in 4 languages, an avid cross country skier and in line skater.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

Dr. Ehlers has authored over 100 scientific papers, has served on the Editorial Boards of Annual Reviews in Medicine, Annual Reviews in Pharmacology and Toxicology, the Journal of Neuroscience, the Journal of Biological Chemistry, and Molecular and Cellular Neuroscience, and sat on advisory committees of the National Institutes of Health. He is a member of the American Society for Cell Biology Governing Council, the Janelia Research Institute Advisory Committee, and the McKnight Endowment Fund for Neuroscience Board of Directors. He serves on the advisory boards of several private foundations, and advises major pharmaceutical, venture, academic, government, and biotech organizations.


ABBVIE, INC.

MICHAEL GOLD

VP Neuroscience Development

METYS PHARMACEUTICALS AG

MICHAEL SCHERZFounder & CEO

Michael Scherz PhD is a Swiss citizen, raised in the USA and southern Germany. He completed his PhD in 1989 in synthetic-medicinal chemistry at the University of Oregon, in Eugene, OR, USA under the guidance of Prof. John Keana, and post-doctoral work in the central nervous system drug discovery group at F. Hoffman-La Roche in Basel, Switzerland, under the guidance of Drs. Ulrich Widmer and René Imhof. In 1992 he joined Procter & Gamble Pharmaceuticals in Cincinnati, OH, USA as synthetic-medicinal chemist. There he took on roles of increasing responsibility in the field of cardiac drug discovery, working on novel Class III anti-antiarrhythmic agents. In 2000 he joined Actelion Pharmaceuticals in Allschwil, Switzerland as head of Actelion’s then-planned US-based drug discovery center. Those plans were scuttled in 2003, and he moved into pre-clinical and clinical research and development at Actelion, ultimately as Vice President, Life Cycle Management, where he was responsible for the global development team efforts for, inter alia, palosuran, almorexant, and ponesimod. In late 2012 he left Actelion, began negotiations with Neurotune AG, and founded Metys Pharmaceuticals in April 2013 to re-start the clinical development of dimiracetam. He has co-authored 17 peer-reviewed publications, and is co-inventor on 18 issued patents. Mr. Scherz is a private pilot and avid hiker.

www.sachsforum.com

Murali joined Abbott/AbbVie in 1993 and subsequently held various positions of increasing responsibility leading research programs and research teams in neuroscience, pain, renal and urology - advancing multiple clinical candidates across these therapeutic areas. He has extensively published in scientific journals and was inducted to the Volwiler Research Society in 2002. From 2009-2013, Murali took on the role as Head of the then newly formed Global External Research group, leading a team focused on developing external innovation strategies with various therapeutic areas, and enabling the identification, diligence and establishment of external collaborations around emerging science, targets, technologies and preclinical assets. He was also responsible for the leadership of AbbVie China R&D Center in Shanghai, since its inception in 2009 and subsequently led the Renal Discovery Therapeutic Area, advancing research programs in Chicago & Shanghai, and via a network of external academic partnerships. Since 2015, he has taken on a leadership position within AbbVie’s Search & Evaluation team, with responsibilities for accessing and advancing opportunities in in the Neuroscience Therapeutic area.

Murali obtained his undergraduate training in pharmacy from Banaras Hindu University, India and a PhD in pharmacology from the School of Pharmacy, SUNY at Buffalo, New York. He completed his post-doctoral training in molecular biology at the Baylor College of Medicine, Houston, Texas and has an MBA degree from the Lake Forest Graduate School of Management, Illinois.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

ABBVIE, INC.

MURALI GOPALAKRISHNAN

Senior Director & Head, Search & Evaluation Neuroscience

Murali Gopalakrishnan is currently Senior Director and Head, Search & Evaluation Neuroscience, at AbbVie, North Chicago, Illinois, USA.


SAVONIX, INC.

MYLEA CHARVAT

Chief Executive Officer & Founder

Dr. Mylea Charvat, a clinical psychologist and translational neuroscientist founded Savonix to address a critical challenge in the health care world – how do we assess the cognitive function of patients on a large scale despite limited dollars and insufficient numbers of specialists.

Mylea completed her fellowship in clinical neuroscience at Stanford School of Medicine and has authored peer-reviewed articles published in well-respected journals. Mylea is committed to advancing the integration of cognitive data into mainstream healthcare and chronic disease management. The inspiration for Savonix came when Mylea’s husband was severely injured and she experienced first-hand the difficulty in attaining the vital health data her husband needed to achieve recovery – including cognitive screening.

She realized that if access was difficult for her, it must be impossible for others with no training, expertise or network. When she reached out to the relatives of other patients, she learned that the challenges were widespread and intractable. Mylea made the decision to leave a decade of work and a prestigious career trajectory toward professorship to found Savonix. She committed herself, instead, to addressing the pervasive challenges in access to neurocognitive assessments and the dire need of millions of people for regular, accessible and affordable tests.

www.sachsforum.com

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

H.C. WAINWRIGHT & CO., LLC

RAGHURAM SELVARAJU Managing Director, Senior Healthcare Analyst, Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC

CENTREXION THERAPEUTICS CORP.

RANDALL STEVENS

Chief Medical Officer

Randall Stevens, M.D. joined Centrexion Therapeutics as the Chief Medical Officer in April 2015. Randall is a board certified internist and rheumatologist with more than 25 years in pharmaceutical medicine. Prior to joining Centrexion, he served as the Corporate Vice President, Head of Inflammation and Immunology Clinical Development of Celgene Corporation. Earlier in his career, Randall spent 11 years at F. Hoffmann La Roche where he was a global leader in inflammation and immunology clinical research. In total, Randall has played an integral role in bringing five drugs to market. Additionally, he is Clinical Professor of Medicine at Robert Wood Johnson School of Medicine and on the faculty since 1987.


Dr. Raghuram Selvaraju, Ph.D., M.B.A., is currently a Managing Director and Senior Healthcare Analyst in the Equity Research Division at H.C. Wainwright & Co., LLC. Dr. Selvaraju’s research focuses on the healthcare sector, particularly with regard to therapeutics and diagnostics. Prior to joining H.C. Wainwright in August 2015, Dr. Selvaraju served as a Managing Director and Senior Healthcare Analyst at MLV & Co., LLC’s Research Division. Dr. Selvaraju previously served as Managing Director, Head of Healthcare Equity Research and Senior Analyst at Aegis Capital Corporation, Research Division from March 2012 until late 2014. Before that, he served as a Senior Vice President and Senior Biotechnology Analyst at Morgan Joseph TriArtisan and Noble Financial Group. From 2009 to 2010, he served as Senior Vice President and Head of Healthcare Equity Research at Hapoalim Securities USA, Inc., Research Division, covering biotechnology, specialty pharmaceuticals, molecular analytics and diagnostics. He possesses over 12 years of experience in healthcare-focused equity research. Before entering Wall Street, Dr. Selvaraju started his career at the Serono Pharmaceutical Research Institute, the European research center for Serono S.A. (at the time Europe’s largest biotechnology company) in 2000. He served as a Technician and Pharmaceutical Researcher at the firm until 2004. Dr. Selvaraju has served as Chairman of Relief Therapeutics Holding AG (formerly THERAMetrics holding AG) since June 02, 2016. He has over 15 years of total experience in the biotechnology and pharmaceutical sectors. Dr. Selvaraju is widely quoted in national publications such as Barron’s and The Wall Street Journal, as well as healthcare industry publications such as The Pink Sheet, BioWorld Today and BioCentury and has appeared numerous times on Bloomberg, CNBC, Business News Network and BTV to comment on drug development trends, healthcare reform policy and pharma and biotech merger and acquisition. He has published articles in leading peer-reviewed journals, presented research at various international scientific conferences and is a co-inventor on several drug patents. Dr. Selvaraju has published sector reports on Alzheimer's disease, multiple sclerosis, stroke, orphan neurological disorders and the Wall Street research on United States healthcare reform policy. He has been ranked on StarMine for earnings accuracy since 2010 and also by The Wall Street Journal’s Best on The Street survey on the basis of portfolio return performance in 2006. While at Serono, he became the youngest-ever recipient of the Serono Pharmaceutical Research Institute's Inventorship Award for exceptional innovation and creativity in 2003. Dr. Selvaraju graduated in 1999 with a Bachelor of Science in Biological Sciences and Technical Writing from Carnegie Mellon University, a Ph.D. in Cellular Immunology and Molecular Neuroscience in 2004, a Master’s of Science in Molecular Biology from the University of Geneva in Switzerland in 2001 on the basis of his drug development research and an M.B.A. from Cornell University’s accelerated one-year program for scientists and engineers in 2005.

www.sachsforum.com

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

ELI LILLY & CO.

RYAN WESTPHAL

Sr. Director Neuroscience External Innovation

Dr. Ryan Westphal, Ph.D. is Senior Director, Search and Evaluation for Eli Lilly Neuroscience responsible for the identification and evaluation of in-licensing and partnering opportunities across all phases of development in Neuroscience.

Dr. Westphal earned a B.S. in Pharmacy from South Dakota State University in 1990 and was a licensed pharmacist (R.Ph.) in the state of South Dakota, He earned his Ph.D. in Pharmacology under the direction of Elaine Sanders-Bush in 1995 from Vanderbilt University working on the molecular mechanisms of serotonin receptor constitutive activity. He then worked at Vanderbilt University as a post-doctoral fellow and then at the Vollum Institute at the Oregon Health Sciences University studying the formation and regulation of protein kinase and phosphatase signaling complexes. Throughout his undergraduate, graduate, and post-doctoral training, Ryan’s research has utilized a variety of molecular, pharmacological and genetic approaches to enhance understanding of the molecular mechanisms of small molecule drugs and their impact on neuronal signaling and networks in the context of mental disorders in psychiatry, neurodegeneration and pain.

In 2000 Ryan joined Bristol-Myers Squibb in Neuroscience Discovery and took on increasing responsibilities for target identification and validation, program leadership, and discovery portfolio management. In his role, he led the Neuroscience Molecular Pharmacology and the Applied Biotechnology Lead Evaluation teams supporting program development from target validation through early clinical discovery advancing several molecules into clinical development. In addition, he was a member of the Neuroscience management team and led discovery alliances with both Lexicon Pharmaceuticals and the Vanderbilt Center for Neuroscience Discovery.

In 2013 Ryan joined FORUM Pharmaceuticals in a business development role as Director of Search and Evaluation responsible for identification and evaluation of external business development opportunities. Subsequently he joined Eli Lilly and Company in 2014 as Senior Director of Search and Evaluation responsible for Neuroscience External Innovation expanding Lilly’s external partnerships and alliances. In his business development activities at BMS, FORUM and Lilly, he has led the out-licensing of clinical assets, established company research collaborations and biotech alliances, and advanced in-licensing opportunities from all phases of development.

Dr. Westphal has authored more than 40 primary research articles and has been an invited speaker at scientific and business development conferences.

TONIX PHARMACEUTICALS HOLDING CORP.

SETH LEDERMAN


Seth Lederman is a physician, scientist and founder and executive officer of innovative biopharmaceuticals companies. Prior to founding Tonix, among the companies Dr. Lederman founded was Targent Pharmaceuticals, which developed late-stage oncology drugs, including pure-isomer levofolinic acid (levoleucovorin). Targent’s assets were sold to Spectrum Pharmaceuticals, which marketed levoleucovorin as Fusilev® for advanced colorectal cancer, where it gained significant market acceptance.

Dr. Lederman served as an Associate Professor at Columbia University from 1996 until April 13, 2017. He joined the faculty of Columbia University’s College of Physicians and Surgeons in 1985, became Assistant Professor of Medicine in 1988, and Associate Professor with tenure in 1996 and Director of the Laboratory of Molecular Immunology in 1997. From 1988 to 2002, Dr. Lederman directed basic science research at Columbia in molecular immunology, infectious diseases and the development of therapeutics for autoimmune


www.sachsforum.com

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

BRIDGEBIO, LLC

SHAFIQUE VIRANI

CEO in Residence

Shafique Virani is currently CEO of Navire Pharma and CEO in Residence at BridgeBio, LLC based in Palo Alto, CA. Until June 2017, he was Vice President, Global Head of Neuroscience, Ophthalmology & Rare disease (NORD) Roche Partnering. Shafique’s responsibilities in this role encompassed all partnering activities within Roche’s NORD franchise, from academic collaborations to licensing and acquisitions. Shafique joined Roche in 2004 and served various roles within medical affairs, marketing and business development in the UK, USA and Switzerland until 2012, when he transitioned to South San Francisco. Shafique is trained as a neurosurgeon in Cambridge, UK and Boston, USA and holds the Fellowship of the Royal College of Surgeons of England.

INNOVATION IN MEDTECH, LLC

STEPHEN LEVIN

Managing Partner

Prior to co-founding Innovation In Medtech, Stephen Levin served as Editor-in-Chief of Medical Devices for Elsevier Business Intelligence, where he directed the company’s editorial coverage of the medical device industry, following Elsevier’s acquisition of Windhover Information in 2008. This included managing the device content for the following publications: IN VIVO, START-UP, MEDTECH INSIGHT, The Gray Sheet, and The Silver Sheet, along with the IN3 medical device partnering conference series. Stephen joined Windhover Information in 1997, where as Executive Editor, he specialized in covering the device industry, distribution, and legal issues. He also served as the company’s General Counsel. He also formerly was an Editor of Health Industry Today, a leading publication in the health care industry.

Prior to joining Windhover, Stephen was Senior Counsel to the US Senate Permanent Sub-committee on Investigations, where he directed Senate investigations into a wide variety of areas including health care fraud and abuse, international organized crime, and corruption in federal contracting programs, while also participating in other Senate investigations including the Whitewater inquiry. Before joining the Subcommittee, he was with the Federal Election Commission (enforcement and regulatory counsel) and the Department of Justice (international criminal law).

diseases. Dr. Lederman is author of numerous scientific articles, and inventor of technologies recognized by a number of issued patents. His fundamental work on the CD40-Ligand (CD154) elucidated the molecular basis of T cell helper function and has led to the development of therapeutic candidates for autoimmune diseases and organ transplant rejection in collaboration with Biogen and UCB. The successful defense of his CD154 patents has led to important precedents in defining the relationship of therapeutics and molecular targets. In collaboration with Prof. David Baltimore (then at Rockefeller University and later MIT), Dr. Lederman identified and functionally characterized the CD40 signaling molecule, TRAF-3. His early work on HIV contributed to the understanding of how the V3 loop of HIV gp120 was involved in fusion with CD4 cell membranes, an early and essential event in viral entry and infection. In addition to his research, Dr. Lederman served as attending physician in the Edward Daniels Arthritis and Autoimmunity Clinic on the Medical Service at Columbia Presbyterian Hospital from 1988-1996.

Dr. Lederman represented U.S. Biotechnology at a Beijing Summit in September 2015 with China’s President Xi Jinping. The Summit was organized by the U.S. Chamber of Commerce and involved a delegation of U.S. CEOs, former U.S. Cabinet officials and leading academic experts.

Dr. Lederman earned an AB from Princeton in Chemistry cum laude in 1979 and an MD from Columbia University’s College of Physicians and Surgeons in 1983. Dr. Lederman trained in internal medicine and rheumatology at Columbia’s Presbyterian Hospital. He was an NIH Physician-Scientist 1985-1990 at Columbia.


www.sachsforum.com

COGNITION THERAPEUTICS, INC.

SUSAN CATALANO

Chief Science Officer and Founder

Dr. Catalano is the founder of Cognition Therapeutics and architect of its proprietary and unique biological discovery platform that is based on unbiased phenotypic screens in the target cell population of mature primary neurons. Using her 15 years of industry experience, she and her team discovered and developed the company’s drug candidate CT1812, currently in clinical testing for the treatment of patients with mild-to-moderate Alzheimer’s disease. Prior to founding Cognition Therapeutics, Dr. Catalano was director of discovery biology for Acumen Pharmaceuticals, leading the team that discovered Acumen’s lead candidates targeting A€ oligomers. Earlier at Rigel, she led the team that pioneered the use of high content phenotypic screening to discover the Aurora kinase inhibitor R763. In scientific leadership roles within the neurophysiology and neuroimaging groups at Roche Palo Alto she led exploratory programs against targets involved in anxiety, depression and schizophrenia. Dr. Catalano received her Ph.D. from U.C. Irvine and postdoctoral training at U.C. Berkeley with Dr. Carla Shatz and at Caltech with Drs. Mary Kennedy and Scott Fraser studying the neurobiology of synaptic plasticity.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

CBT ADVISORS

STEVE DICKMAN


CBT Advisors Founder-CEO Steve Dickman has worked in the biotechnology and venture capital industries for twenty years. He founded CBT Advisors in 2003 after a four-year stint as a venture capitalist with TVM Capital, where his investments included Sirna Therapeutics, which was acquired in 2006 by Merck for $1.1 billion, and bluebird bio, which went public on Nasdaq (BLUE) in 2013 and had a $6.8 billion valuation in November, 2017. His firm CBT Advisors has served over two hundred fifty clients, including both public and private com-panies. Steve publishes from time to time on Forbes and Boston Biotech Watch.

CBT Advisors works on analysis and storytelling in all areas of life sciences including drug discovery and clinical development, molecular diagnostics, research tools and software and digital health. CBT Advisors pursues projects of three basic types:

- Drafting of prospectus text for later-stage companies

- Story and pich development for earlier-stage companies including slide decks, business plans, market analysis and competitive positioning.

- Strategic reviews of private biotech and life sciences companies. On behalf of management teams and investors, we apply our understanding and insight into the positioning and fund-raising needs of VC-backed and angel-backed companies in order to drive changes in strategy, awareness of competitors, improvements in positioning and adjustment of goals and milestones.

Our clients, including NuCana, ArgenX and CRISPR Therapeutics, have had fifteen successful Nasdaq IPOs, two EuroNext IPOs and seven successful reverse mergers. Our earlier stage clients, including Evotec, Crescendo Biologics and MiNA Therapeutics, have gone on to other significant transactions or milestones.

CAMBRIDGE COGNITION

STEVEN POWELL


Dr Powell graduated in microbiology from the University of Wales and was awarded a PhD from the University of Aberdeen. He has over thirty years operational and investment experience in pharmaceutical and healthcare companies in the UK, USA and Scandinavia. Including his current role at Cambridge Cognition, he has held five CEO roles, three in public companies. In 2003, he joined Gilde Healthcare, a pan-European life sciences investment fund as a partner and remained an adviser to the fund until 2016.


www.sachsforum.com

ADDRESS

220 East 70 Street

New York, NY 10021

USA

WEBSITE

www.asdera.com

COMPANY TYPE

Private

YEAR FOUNDED

2013

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

ASDERA

COMPANY PROFILE


ASDERA utilizes a computational drug discovery platform to identify components in the etiology of complex diseases, identify targets, generate IP, and outlicense first-in-class disease-modifying drugs against diseases with high unmet needs.

The first such asset, a drug to prevent children who develop autism from becoming non-verbal, was outlicensed to QBioMed (QBio).

The current lead is a family of related disease-modifying drugs (CoM pat pending) that target an early common pleiotropic component in the etiology of several neurodegenerative diseases (including Alzheimer's, Parkinson's, ALS, and multiple sclerosis), rather than trying to repair damage later in the disease pathways. Other assets include drugs (CoM pat. pending) against carcinomas, atherosclerosis, and other age-related diseases. The platform has also been successfully applied to analyze clinical trials of 600-2000 subjects to identify patient populations most likely to respond to therapy.

SECTOR

Biotechnology

Pharmaceuticals/Licensing

FINANCIAL SUMMARY

ASDERA is privately funded and receives revenue from outlicensing. ASDERA is

seeking to outlicense or collaborate on advancing additional assets to market.

PIPELINE PRODUCT 1:

ASD-005 / Stage 2b/3 under 505(b)(2)

PIPELINE PRODUCT 1:

ASD-005 is a treaatment of neurodegenerative diseases that targets a pleiotropic risk factor of several neurodegenerative diseases, including Alzheimer's (AD), Parkinson's (PD), and multiple sclerosis (MS).

In short, ASDERA's drug discovery platform pointed to epistasis between - upregulated endocytosis (e.g., of APP, a-synuclein, and myelin) and age-dependent decline in lysosomal function.

ASD-005 treats neurodegenerative diseases by down-regulating endocytosis to prevent lysosomes from "overflowing" with Ab, tau, or myelin, respectively.

From the first human studies, ASD-005 is resorbed from the intestine and also reduces inflammation by downregulating arachidonic acid upstream of the targets of COX/LOX inhibitors.

PIPELINE PRODUCT 2:

ASD-006 / Stage 2b/3 under 505(b)(2)

PIPELINE PRODUCT 2:

ASD-006 is an intervention to prevent deveral age-related conditions, including

several neurodevelopmental diseases (Alzheimer's, Parkinson's, multiple sclerosis).

In short, ASDERA's drug discovery platform pointed to epistasis between upregulated

endocytosis (see ASD-005) and age-dependent decline in lysosomal function.

www.sachsforum.com

ADDRESS

220 East 70 Street

New York, NY 10021

USA

WEBSITE

www.asdera.com

COMPANY TYPE

Private

YEAR FOUNDED

2013

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


ASD-006 prevents neurodegenerative diseases and other age-related conditions, such as cancer (breast cancer, prostate cancer, other carcinomas) and metabolic/inflammatory diseases (atherosclerosis, NASH, ...) by down-regulating endocytosis to prevent lysosomes from "overflowing" with various disease-specific molecules (LDL, cholesterol, ... )

SECTOR

Biotechnology


INVESTMENT & LICENCING OPPORTUNITY 1:

ASD-005: Treatment of AD/PD/MS

OPPORTUNITY 1:

Novel drug (composition-of-matter patent pending) to treat Alzheimer's, Parkinson's,

and multiple sclerosis. (see Pipeline Product 1 for details).


ASD-006: Prevention of neurodegeneration

OPPORTUNITY 2:

Novel intervention (composition-of-matter patent pending) to prevent several age-related conditions, including neurodegenerative, metastatic, metabolic, and inflammatory diseases (see Pipeline Product 2 for details).

www.sachsforum.com

AZTHERAPIES, INC.

COMPANY PROFILE

Preventing Alzheimer’s disease progression, early We are at the forefront of the disovery, development and commercialization of novel Alzheimer’s disease therapeutics that will fundamentally improve patient outcomes, quality of life, and disease management. Preventing Alzheimer’s disease progression remains a critical, unmet need for millions of people in the US and worldwide. Our advanced knowledge of Alzheimer’s disease biology, combined with our proprietary scientific discoveries, and clinical and biomarker imaging expertise, provides AZTherapies with unique potential to develop novel therapies to impact Alzheimer’s disease progression.

ADDRESS

222 Berkeley Street

12th Floor

Boston, MA 02116

USA

WEBSITE

www.aztherapies.com

EMAIL

kgreenfield@aztherapies.

com

PHONE

+1 617 318 3411

COMPANY TYPE

Private

SECTOR

Biotechnology

YEAR FOUNDED

2011

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com

BIONOMICS LTD.

COMPANY PROFILE

Bionomics is a biopharmaceutical company dedicated to making better treatments for cancer, central nervous system disorders such as anxiety, depression and Alzheimer’s disease. I invite you to spend a few minutes exploring our website and getting to know us. Our exceptionally talented team is driven by a shared commitment to make a difference in diseases with inadequate treatment options. We are in a strong growth phase with our world-class portfolio of promising drug candidates from early to advanced stages of clinical development. This portfolio is fed by highly productive drug discovery platforms that includes MultiCore®, our proprietary chemistry capability. At the core of our business is strategic partnering. We partner with large pharmaceutical companies to get our drugs through the later stages of development and into the market as rapidly as possible. This means we can focus our strengths in innovative drug discovery to extract as many “shots on goal” from our diverse pipeline in the quest to create the world’s new blockbuster drugs. We have a passion for what we do and we work with the best in the world to deliver meaningful outcomes from our discoveries. We look forward to you accompanying us on this extremely valuable journey.

ADDRESS

31 Dalgleish Street

Thebarton SA 5031

Australia

WEBSITE

www.bionomics.com.au

EMAIL

[email protected]

PHONE

+1 618 8354 6100

COMPANY TYPE

Public

TICKER

[ASX: BNO]

SECTOR

Biotechnology

YEAR FOUNDED

1999

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

MANAGEMENT TEAM

Dr Deborah Rathjen - CEO & Managing DirectorMr Steven Lydeamore - CFO Mr Jack Moschakis - Legal Counsel & Company Secretary Dr Sue O'Connor - VP, Neuroscience ResearchDr Tina Lavranos - Senior Director, CancerDr Lorna Mitchell - VP, Medicinal Chemistry

PIPELINE PRODUCT 1:

BNC101

PIPELINE PRODUCT 1:

BNC101 is a Phase I cancer stem cell targeting antibody. Preclinical studies have demonstrated that BNC101 significantly reduces CSC frequency and prevents tumour re-growth in long term studies. BNC101 increases survival and inhibits weight loss in a cachectic colorectal cancer tumour model.

PIPELINE PRODUCT 2:

BNC105

PIPELINE PRODUCT 2:

BNC105 is a best in class, novel Vascular Disrupting Agent (VDA) being developed by Bionomics for the treatment of solid tumours.

Phase II trials are ongoing in renal cancer, mesothelioma and a Phase II trial in ovarian cancer will commence 1H, 2012


www.sachsforum.com


ADDRESS

31 Dalgleish Street

Thebarton SA 5031

Australia

WEBSITE

www.bionomics.com.au

EMAIL

[email protected]

PHONE

+618 8354 6100

COMPANY TYPE

Public

TICKER

[ASX: BNO]

SECTOR

Biotechnology

YEAR FOUNDED

1998

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

PIPELINE PRODUCT 3:

BNC210

PIPELINE PRODUCT 3:

Bionomics' first in class small molecule BNC210, is a negative allosteric modulator of the α7 nicotinic acetylcholine receptor in development for the treatment of anxietydisorders, co-morbid anxiety and depression. BNC210 is currently enrolling PTSD patients in the USA and Australia for a Phase II trial which is expected to read out in Q3, 2018. Single doses of BNC210 have been evaluated in generalised anxiety disorder patients in an fMRI study – the emotional faces task, and a behavioural study

- the joystick operated runway task. Lorazepam was used a positive control in this in this trial. BNC210 treatment reduced bi-lateral amygdala reactivity to fearful faces relative to placebo, and was more effective than Lorazepam. Similarly, in the behavioural task, BNC210 reduced thread avoidance behaviour in the GAD patients and again outperformed Lorazepam. These data indicated that BNC210 reduced activation of anxiety-related neural circuits and anxiety-related behaviours with equivalent efficacy to Lorazepam. BNC210 lacks the side effects seen with benzodiazepines e.g., it is not sedating, does not cause memory or motor impairment and is not addictive.

In preclinical studies, BNC210 has been safe and efficacious in animal models of anxiety with equivalent efficacy to benzodiazepines. It has also shown antidepressant activity in the rat forced swim test and enhances fear extinction in a mouse model of contextual fear conditioning.

Bionomics is seeking a partner to take BNC210 into Phase III studies and to market.

www.sachsforum.com

BONTI

COMPANY PROFILE

Bonti is a privately-held, clinical-stage, rapidly emerging biotechnology company developing a next generation neurotoxin for therapeutic and aesthetic indications for patients with unmet needs. Founded by world class neurotoxin experts with proven success, the Bonti team has unsurpassed neurotoxin, aesthetic and pain expertise. Bonti will improve lives by successfully addressing key unmet needs in markets with significant addressable opportunities. Bonti’s lead product candidate, EB-001, is an investigational botulinum neurotoxin serotype E (BoNT/E). EB-001 has a mechanism of action similar to the marketed botulinum neurotoxin serotype A (BoNT/A) products though it has a differentiated clinical profile. EB-001 has a fast onset of action (within 24 hours) and short duration of effect (about 3 – 4 weeks). EB-001’s unique target clinical profile may be well suited for a vast range of therapeutic, e.g., for the effective treatment of post-surgical and non-surgical musculoskeletal pain, and aesthetic uses.

ADDRESS

4921 Birch St., Suite 120

Newport Beach,

CA 92660

USA

WEBSITE

www.bonti.com

COMPANY TYPE

Private

SECTOR

Biotechnology

YEAR FOUNDED

2015

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com


CAVION

COMPANY PROFILE

Cavion is a clinical-stage pharmaceutical company with an innovative mindset and compassionate culture. Cavion closed a Series A venture capital financing in late 2016. Combining those investors’ industry capabilities with Cavion’s science and expertise has put us well on the road to developing our promising Cav3 modulators for movement disorders and rare, pediatric epilepsies. Committed to putting people in the center, Cavion’s first neurology clinical trial – the T-CALM trial of CX-8998 in essential tremor – is now recruiting subjects.

MANAGEMENT TEAM

Andrew Krouse, President & Chief Executive Officer

Spyros Papapetropoulos, EVP, Head of R&D, Chief Medical Officer

Mike Innes, Business Development

FINANCIAL SUMMARY

Cavion seeks to expand and accelerate the development of improved treatments for epilepsy and pain through collaboration. We welcome the opportunity to expand our relationships with neurology innovators and prospective commercial partners.

PIPELINE GRAPHIC

ADDRESS

600 East Water Street,

Suite ECharlottesville,

VA 22902

USA

WEBSITE

www.cavionpharma.com

EMAIL

[email protected]

PHONE

+1 434 200 8442

COMPANY TYPE

Private

SECTOR

Biotechnology

YEAR FOUNDED

2006

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

www.sachsforum.com

CENNA BIOSCIENCES, INC.

COMPANY PROFILE

Cenna Biosciences Inc. is a privately-held biopharmaceutical company dedicated to the discovery and development of novel drugs to prevent and treat Alzheimer's disease (AD). Cenna was founded in 2006 as a California C-corporation to translate over a decade's academic research at the University of California San Diego (UCSD) by the inventors of the technology. The research to date has been funded by non-diluting NIH and other grants.

Cenna has a novel and different proprietary patented technology that arrests the underlying cause of the disease, the inappropriate deposition of the toxic species, Aß, in the brains of patients with AD. Cenna’s technology also addresses previous failures by others that were due to the targeting of the ß- and gamma-secretases. Cenna’s novel technology, that does not target the secretases, has yielded several peptide and small molecule drug candidates with the ability to inhibit the production of Aß in vitro, in a transgenic mouse model of AD in AD patient-derived induced stem cells, without modifying or inhibiting either ß- or gamma-secretase activities. Cenna’s technology is also the earliest in terms of intervention, as it stops the Aß from being produced, as opposed to dealing with the effects of Aß once it has accumulated. Cenna’s technology is expected to stop the disease in its tracks. It is anticipated that Cenna’s therapeutics will have a significant impact in both treatment and prevention modes and be useful throughout the course of disease. Cenna's technology is covered by 6 granted US patents and 7 foreign patents. Preclinical studies are in progress with IND filing for the first candidate, P8, planned for 2018. The Exit Strategy is for Cenna to be acquired after the successful completion of Clinical Phase IIA.

ADDRESS

505 Coast Blvd South,

Suite 302

La Jolla, California 92037

USA

WEBSITE

www.cennabiosciences.com

EMAIL

ndewji@cennabiosciences.

com

PHONE

+1 858 456 0820

COMPANY TYPE

Private

SECTOR

Biotechnology

YEAR FOUNDED

2006

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

MANAGEMENT TEAM

Nazneen Dewji, Ph.D. Founder, President

Ruprecht Von Buttlar, Business Development Adviser (Procopio)

John Campbell, Corporate Attorney (Morrison Foerster) Michael N.

Krupp, Ph.D., Licensing Adviser

Cary Miller, Ph.D., JD, Patent Attorney (Jones Day)

Phoebe Mounts, Ph.D., JD Counsel for Regulatory Affairs and FDA

Facilitation (Morgan Lewis)

Key Shin, JD, Contracts Attorney (Morgan Lewis)

Julie Wilkes, B.S., Director of Operations

FINANCIAL SUMMARY

$14.5 million in NIH and other grants

$664,000 loans from Founders

PIPELINE PRODUCT 1:

Peptide drug candidate P8/Preclinical. IND expected in 2018

PIPELINE PRODUCT 1:

The basic pathology of the disease includes the production and accumulation of Ab. CENNA’s candidate drugs reduce the production of Aß. They are small peptides derived from Presenilin-1 which is part of the g-secretase complex. CENNA’s peptides inhibit the production of Aß by specifically binding APP at a different site from the ß- and gamma-secretase cleavage sites and arresting its processing to Aß (Dewji, N.N. et al (2015) PLoS ONE 10(4): e0122451). Importantly, these peptide-induced reductions of total Aß and Aß40 and 42 do not modify or inhibit either ß- or gamma-secretase



activities. Our lead candidate, P8 inhibits the production of Aß in vitro, in a Tg mouse model of AD and in patient-derived stem cells by over 50%, is stable, and can be delivered to the brain. Preclinical studies are in progress with IND filing planned for 2018.

ADDRESS

505 Coast Blvd South,

Suite 302

La Jolla, California 92037

USA

WEBSITE

www.cennabiosciences.com

EMAIL

ndewji@cennabiosciences.

com

PHONE

+1 858 456 0820

COMPANY TYPE

Private

SECTOR

Biotechnology

YEAR FOUNDED

2006

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

www.sachsforum.com


Seeking a $5 million investment to complete the development to IND and Phase 1 clinical

trials.

OPPORTUNITY 1:

CENNA is seeking a Pre-Series A round of $5M to fund operations for the next 12-24 months in order to advance its development programs, hire new staff, and continue commercialization activities. The primary activities are to develop CENNA’s existing technology to complete the pre-clinical development of P8. CENNA will develop a preclinical scientific package that will include the necessary experimentation in animals required for filing an IND.

Cenna is also interested in entering into strategic collaborative partnerships with pharmaceutical companies to complete remaining preclinical efforts and continue onto clinical studies. Cenna can offer an exclusive license to its technology with a commitment to advance the science through the right partnership.

www.sachsforum.com

CLICK THERAPEUTICS, INC.

COMPANY PROFILE

Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments. Click created the term Digital Therapeutics™ in 2012 based on the premise that mobile software can be an effective treatment for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click Therapeutics' digital interventions enable change within individuals, and can be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Click's lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.

PIPELINE GRAPHIC

ADDRESS

101 Avenue of the

Americas, 8th Floor

New York, NY 10013

USA

WEBSITE www.clicktherapeutics.com

EMAIL

[email protected]

PHONE

+1 646 844 2158

COMPANY TYPE

Private

SECTOR

Biotechnology

Medical Devices

YEAR FOUNDED

2012

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


MANAGEMENT TEAM

David Benshoof Klein, Co-Founder & CEO

Victor Gao, Chief Innovation & Engagement Officer

Ted Silver, Chief Financial Officer

Joel Sangerman, Chief Commercial Officer

Christopher Jordan, Chief Technology Officer

Brian Iacoviello, PhD, Director of Scientific Affairs

Click has raised ~$9 million since 2014, with our most recent raise being completed in

April of 2017. Magellan Health (NASDAQ: MGLN) is currently our largest investor.

Regarding our plans for reimbursement, we are working in close partnership with

Magellan, who manage formularies for 53 commercial insurance plans, 26 US states'

medicaid plans, and is also one of the nation's largest behavioral health insurers.

FINANCIAL SUMMARY

www.sachsforum.com

ADDRESS

101 Avenue of the

Americas, 8th Floor

New York, NY 10013

USA

WEBSITE www.clicktherapeutics.com

EMAIL

[email protected]

PHONE

+1 646 844 2158

COMPANY TYPE

Private

SECTOR

Biotechnology

Medical Devices

YEAR FOUNDED

2012

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


PIPELINE PRODUCT 1:

CT-152 / FDA Registration Study for Major Depressive Disorder

PIPELINE PRODUCT 1:

ClickEFMT™

After two successful randomized controlled trials, an fMRI imaging study supportive of our hypothesis of the intervention's neuroplastic effect, and a meeting with FDA, our lead prescription program is entering a phase 3 FDA registration study for the treatment of Major Depressive Disorder in adults. ClickEFMT integrates a patent-pending cognitive-emotional training exercise with a proprietary messaging program conveying psychotherapy within a robust engagement platform to provide non-pharmacological treatment for major depressive episodes.

PIPELINE PRODUCT 2:

CT-141 / FDA Registration Study for Insomnia

PIPELINE PRODUCT 2:

Clickadian™

A fully digital program for insomnia. The core component of our insomnia program is a digital cognitive behavioral therapy (CBT) program called RESTORE™. RESTORE has been clinically proven to improve sleep in more than 80% of participants, increase sleep time by 50 minutes per night, and to be as effective as face-to-face therapy. Clickadian integrates RESTORE with Click’s proprietary cognitive restructuring, sleep hygiene management, stimulus control, sleep restriction, and relaxation modules. The program is personalized using our machine learning and engagement platform.

PIPELINE PRODUCT 3:

CT-201 / Development Ready for Alzheimer's Disease

PIPELINE PRODUCT 3:

Clickmentia™

A digital solution which addresses health and cost issues by supporting patient-caregiver dyads living with neuro-cognitive disorders such as Alzheimer's disease. Through the use of a mobile application designed specifically for this population, the digital program utilizes the patient's own care and support network to engage users, track behavior, and provide tailored support at the right time and in the right context. Clickmentia™ harnesses the power of real-time predictive analytics and at-home caregiver strategies.

www.sachsforum.com

COGNITION THERAPEUTICS, INC.

COMPANY PROFILE

Cognition Therapeutics has leveraged proprietary biology and chemistry platforms to develop a pipeline of disease-modifying small molecule drug candidates to treat neurocognitive disorders. The company’s lead candidate, CT1812, is a proprietary first-in-class, orally available small molecule in Phase 2 clinical development for the treatment of mild-to-moderate Alzheimer’s disease. In October 2017, the U.S. FDA granted CT1812 Fast Track designation.

ADDRESS

2403 Sidney St # 261,

Pittsburgh, PA 15203

USA

WEBSITE

www.cogrx.com

EMAIL

[email protected]

PHONE

+1 412 481 2210

COMPANY TYPE

Private

SECTOR

Biotechnology

YEAR FOUNDED

2007

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

MANAGEMENT TEAM

Kenneth I. Moch, President & CEO

Susan Catalano, PhD, Chief Science Officer

Hank Safferstein, PhD, JD, MBA, SVP, Corporate Development

Stephen DiPalma, Chief Financial Officer

Gilbert M. Rishton, PhD, Chemistry Advisor

Michael Grundman, MD, Chief Medical Advisor

Celine Houser, Vice President, Clinical Operations

PIPELINE PRODUCT 1:

CT1812 / Phase 2

PIPELINE PRODUCT 1:

CT1812 is a highly brain penetrant compound in development for the treatment of mild-to-moderate Alzheimer’s disease. By targeting the sigma-2 receptor complex on neuronal synapses, CT1812 displaces toxic beta amyloid oligomers from their binding sites on brain cells and clears them into the cerebrospinal fluid. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss.

Phase 1b/2a clinical results were presenting at a CTAD late-breaker in November 2017. These data showed that plasma CT1812 concentration increased dose proportionally, and all CSF concentrations yielded an estimated brain receptor occupancy greater than 80%, which was previously identified as the threshold needed to demonstrate efficacy. In clinical studies to date, CT1812 has been safe and well-tolerated in patients with mild-to-moderate Alzheimer’s disease. Further, administration of CT1812 to Alzheimer’s patients has had a positive influence on biomarkers of synapse recovery, providing confirmation of its target engagement.

OPPORTUNITY 1:Cognition is currently seeking Series C financing of approximately $25 million to advance the clinical development program for CT1812. These funds will be supplemented by significant newly granted non-dilutive funding from the National Institute of Aging, exceeding $8 million, to support several clinical trials to be initiated in 2018 focused on the mechanism of action, safety and efficacy of CT1812.


In clinical studies to date, CT1812 has been safe and well-tolerated in patients with mild-to-moderate Alzheimer’s disease. Late-Breaking Phase 1b/2a data presented at the CTAD meeting in November 2017 showed that CT1812 has a positive influence on biomarkers of synapse recovery, providing confirmation of target engagement. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss, consistent with the compound’s proposed mechanism of action.

www.sachsforum.com

EMERALD HEALTH THERAPEUTICS, INC.

COMPANY PROFILE

Emerald Health Therapeutics, Inc. is a diversified cannabis company positioned to take advantage of the significant projected growth in different segments of the cannabis industry. The target segments are Pharmaceuticals, Botanicals (Medical and Recreational), and Bioceuticals. Each investment leverages the scientific rigor, federal regulatory compliance, and life-science expertise of Emerald Health Sciences’ leadership.

WEBSITE

www.emerald.life

COMPANY TYPE

Public

TICKER

[TSXV: EMH]

SECTOR

Biotechnology

YEAR FOUNDED

2013

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


ADDRESS

Canada

www.sachsforum.com

ADDRESS

500 International

Drive Suite 200

Mt. Olive, New Jersey

07828USA

WEBSITE

www.flowonix.com

EMAIL

[email protected]

PHONE

+1 973 426 9229

COMPANY TYPE

Private

SECTOR

Biotechnology

YEAR FOUNDED

2005

FLOWONIX MEDICAL, INC.

COMPANY PROFILE

Flowonix is a medical device company dedicated to helping those who suffer from chronic disorders. Our team has decades of experience developing unique and reliable medical devices to improve lifestyles. Using one of a kind technology, Flowonix has developed an implantable drug pump designed to deliver therapeutic drugs into the spine to relieve a variety of chronic disorders and help patients return to normal lives. Currently, Flowonix is focused on alleviating chronic pain. We are dedicated to working with healthcare professionals to help ease suffering and allow people to reclaim their lives through innovation and therapy advancements.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com

INVISIO PHARMACEUTICALS

COMPANY PROFILE

Invisio has raised seed funding from two US financial organisations to initiate launches of products in the UK during 2018. The team has particular experience in Psychiatry and Neurology small molecule therapeutics. Invisio is targeting New Therapeutic Entity products commercialising through the unlicensed to licensed, supergenerics and orphan drug designation routes.

Initial sales are anticipated during qtr1/2018 and first marketing authorisations are anticipated through 2019/2020.

Further funding will allow us to accelerate our growth plans.

ADDRESS

58 Kingsway,

London, SW14 7HW

United Kingdom

WEBSITE

www.invisiopharm.com

EMAIL

[email protected]

PHONE

+44 208 133 8389

COMPANY TYPE

Private

SECTOR

Biotechnology

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


Drug DeliveryPharmaceuticals/Licensing

MANAGEMENT TEAM

Russ Pendleton, CEO

Andrew Tittershill, COO

Seed Funding in place.

FINANCIAL SUMMARY

PIPELINE GRAPHIC

PIPELINE PRODUCT 1:

Flavoured Oral Liquid version of an existing cognitive dysfunction product for Cognitive Dysfunction/Daytime Sleepiness associated with Alzheimers, Parkinsons, Schizophrenia, Insomnia, Cancer Therapy Patients.

PIPELINE PRODUCT 1:

INV701 Cognitive Dysfunction

www.sachsforum.com

ADDRESS

58 Kingsway,

London, SW14 7HW

United Kingdom

WEBSITE

www.invisiopharm.com

EMAIL

[email protected]

PHONE

+44 208 133 8389

COMPANY TYPE

Private

SECTOR

Biotechnology

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


Drug DeliveryPharmaceuticals/Licensing

PIPELINE PRODUCT 1:

Flavoured Oral Liquid version of an existing cognitive dysfunction product for Cognitive Dysfunction/Daytime Sleepiness associated with Alzheimers, Parkinsons, Schizophrenia, Insomnia, Cancer Therapy Patients.

PIPELINE PRODUCT 1:

INV701 Cognitive Dysfunction

PIPELINE PRODUCT 2:

Flavoured Oral Liquid Version of an existing parkinsons therapy.

PIPELINE PRODUCT 2:

INV702 AntiParkinsons

PIPELINE PRODUCT 3:

Combination Oral Liquid therapy for Alzheimers.

PIPELINE PRODUCT 3:

INV703 AntiAlzheimers

OPPORTUNITY 1:

Transdermal Therapy for Depression


TD AntiDepressant

OPPORTUNITY 2:

Formulation Development complete, just requires BE study for US. Could launch now as unlicensed medicine in Europe/other territories.


Long Acting Tablet Aripiprazole for Once Weekly Therapy

OPPORTUNITY 3:

Reprofiled antidepressant with libido enhancement. Ready for European dossier submission end 2018.


Libido Enhancing Antidepressant

www.sachsforum.com

KALGENE PHARMACEUTICALS, INC.

COMPANY PROFILE

Preventing Alzheimer's disease progression remains a critical unmet need for millions of

people worldwide.

Kalgene is developing a novel fusion protein therapeutic for slowing the progression of Alzheimer's disease, with technology licensed from the National Research Council of Canada. The therapeutic targets the toxic soluble amyloid and the clinical program will focus on patients with early clinical signs of cognitive decline, before progressive neural damage causes dementia.

Today we've completed pre-clinical proof of concept work in partnership with the NRC and McGill University. These studies have shown that the development candidate passes through the blood brain barrier and rapidly induces CSF-amyloid-beta clearance. PET studies in rat models of the disease showed dramatic plaque removal. In an aged rat disease model, neuronal connectivity using diffusion weighted MRI was vastly improved, hippocampal volume was increased and no increase in micro-hemorrhages was observed.

ADDRESS

210, Boul. Jean-Leman

Candiac

QC J5R 6E6

Canada

WEBSITE

www.kalgene.com

EMAIL

[email protected]

PHONE

+1 604 375 4519

COMPANY TYPE

Private

SECTOR

Biotechnology

YEAR FOUNDED

2006

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com


K-PAX PHARMACEUTICALS, INC.

COMPANY PROFILE

K-PAX Pharmaceuticals (Mill Valley, California) is a SF Bay Area biopharmaceutical company focused on identifying the first disease-modifying treatment for Parkinson’s disease (PD). We have been in business for over ten years and are revenue positive.

There is now agreement that the trigger and driver of Parkinson’s disease is a significant failure of mitochondrial function in dopaminergic neurons. This leads to a buildup of free radicals within these cells that denatures alpha synuclein and other structural proteins. These neurons then progressively die via apoptosis.

We have successfully developed a mitochondrial modulator technology platform that treats the significant mitochondrial dysfunction inherent in Parkinson’s disease.. This technology makes use of several key compounds that, though previously available, have never been combined. When combined, these compounds exert a synergistic effect on restoring healthy mitochondrial function and promoting improved neuronal health leading to a reduction in both motor and non-motor PD symptoms.

KPAX002 has strong potential to delay Parkinson’s disease progression and begin PD patients on the road toward improvement and recovery.

K-PAX Pharmaceuticals is seeking strategic investors or a co-development partner to assist us in fully completing our Phase 2 program and developing this breakthrough therapy into the first approved treatment to modify the course of Parkinson’s disease.

PIPELINE GRAPHIC

ADDRESS

655 Redwood Highway,

Suite #346

Mill Valley, CA 94941

USA

WEBSITE

www.kpaxpharmaceuticals.

com

EMAIL

[email protected]

PHONE

+1 415 381 7565

COMPANY TYPE

Private

SECTOR

Biotechnology


YEAR FOUNDED

2005

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

www.sachsforum.com

MARINUS PHARMACEUTICALS, INC.

COMPANY PROFILE

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, an extensive safety database, and convenient dosing to improve the lives of patients suffering from drug-resistant seizures and neuropsychiatric disorders.

Ganaxolone is a positive allosteric modulator of GABAA that acts on a well-characterized target in the brain known to have both anti-seizure and anti-anxiety effects. Ganaxolone is being developed in three different dose forms (IV, capsule and liquid) intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is currently evaluating ganaxolone in women with postpartum depression and preparing to initiate studies in children with CDKL5 deficiency disorder and patients with status epilepticus, both of which are orphan indications.

WEBSITE

www.marinuspharma.com

EMAIL

Lcaperelli@marinuspharma.

com

PHONE

+1 484 801 4674

COMPANY TYPE

Public

TICKER

[NASDAQ: MRNS]

SECTOR

Biotechnology

YEAR FOUNDED

2003

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

PIPELINE GRAPHIC

MANAGEMENT TEAM

Christopher Cashman, CEO

Edward Smith, CFO

Dr. Lorianne Masuoka, CMO


ADDRESS

170 N Radnor

Chester RD

Suite 250

Radnor, PA 19087

USA

www.sachsforum.com


PIPELINE PRODUCT 1:

Ganaxolone (liquid suspension)

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

PIPELINE PRODUCT 1:

Ganxolone (liquid suspension) was evaluated in a Phase 2 trial in children with rare, pediatric epilepsies. Ganaxolone reduced seizures, increased seizure free days and was generally safe and well-tolerated in children with PCDH19 epilepsy, CDKL5 deficiency disorder and LGS. Marinus is planning to conduct a late-stage clinical trial with ganaxolone in children with CDKL5 deficiency disorder in early-2018.

PIPELINE PRODUCT 2:

Ganaxolone (IV)

PIPELINE PRODUCT 2:

Ganaxolone IV is being evaluated in a Phase 2 clinical study in women with severe postpartum depression (Magnolia Study). The double-blind, placebo-controlled, dose escalation study is currently enrolling patients. Data from the initial cohort of patients is expected in the first quarter of 2018.

Marinus is also initiating a study to evaluate ganaxolone IV in patients with status epilepticus.

PIPELINE PRODUCT 3:

Ganaxolone (capsules)

PIPELINE PRODUCT 3:

Marinus is initiating a Phase 2 clinical study to evaluate oral ganaxolone in women with

moderate postpartum depression (Amaryllis Study). Data from the study is expected in 2018.

WEBSITE

www.marinuspharma.com

EMAIL

Lcaperelli@marinuspharma.

com

PHONE

+1 484 801 4674

COMPANY TYPE

Public

TICKER

[NASDAQ: MRNS]

SECTOR

Biotechnology

YEAR FOUNDED

2003

ADDRESS

170 N Radnor

Chester RD

Suite 250

Radnor, PA 19087

USA

www.sachsforum.com

METYS PHARMACEUTICALS AG

COMPANY PROFILE

Metys Pharmaceuticals is developing dimiracetam for the prevention of chemotherapy-induced painful peripheral neuropathy. In the US alone, in a single year, more than 400’000 patients suffer from the neuropathy caused by their life-saving cancer treatment. No drug has been approved to prevent or treat this condition. Dimiracetam is an orally active, small molecule with more than 200 patients’ safety and tolerability data; dimiracetam is highly effective in preventing and treating chemotherapy-induced neuropathy in rodents. Metys Pharmaceuticals is preparing the first dedicated efficacy study of dimiracetam in this indication.

ADDRESS

Leimenstrasse 57

4051 Basel

Switzerland

WEBSITE

www.metys-pharma.ch

EMAIL

[email protected]

PHONE

+41 79 408 79 82

COMPANY TYPE

Private

SECTOR

Biotechnology

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


YEAR FOUNDED

2013

www.sachsforum.com

NEUROACTIVA, INC.

COMPANY PROFILE

NeuroActiva, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of new drugs to treat Alzheimer’s disease. We have 2 drugs, which are in clinical trials Phase 1 and Phase 2 focusing on treatment of Alzheimer’s disease.

1. Traneurocin (NA-831), a novel neuroprotective and neurogenesis agent for treatmentof Alzheimer's disease. NA-831 is an endogenous compound, i.e. already in existence in the brain. It has an excellent safety profile with no toxicity observed. The Phase is scheduled to be completed in March 2018.

2. Our second drug candidate, Vineurocin (NA-704) is a recombinant human growthhormone that modulates the aging process in humans. NA-704 exhibits neuroprotection and neurogenesis, which has been demonstrated as a strong candidate for treatment of Alzheimer’s disease and other neurological disorders. The NA-704 Phase 2 will be from from June 2018 to May 2019.

NeuroActiva has developed a new controlled release intravenous drug delivery, known as the MICROS Infusion System, which has been approved by the FDA for marketing in the USA. MICROS can be prefilled with a customized dosage of NA-704 to be available as a premixed and ready to use package.

ADDRESS

1460 Tully Road

Suites 602

San Jose, 95122

USA

WEBSITE

www.neuroactiva.com

PHONE

+1 415-941-3133

COMPANY TYPE

Private

SECTOR

Biotechnology

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


EMAIL

[email protected]

YEAR FOUNDED

2014

FINANCIAL SUMMARY

MANAGEMENT TEAM

Lloyd Tran, Chief Executive Officer

Fern Vu, Chief Financial Officer

Brian Tran MD, Medical Director

Luke Neave, Director of Business Development

Peter Hung, Director of Clinical Affairs

More than 7.5 million has been invested in NeuroActiva over the past 3 years.

PIPELINE GRAPHIC

www.sachsforum.com

NEURALSTEM, INC.

COMPANY PROFILE

Neuralstem (NASDAQ:CUR) is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. Our lead asset, NSI-189, is a new chemical entity in clinical development for major depressive disorder (MDD) and in preclinical development for Angelman syndrome, irradiation-in-duced cognitive impairment, neuropathy associated with Type 1 and Type 2 diabetes, and stroke. Our lead stem cell therapy candidate, NSI-566, is a spinal cord-derived neural stem cell line being tested in Amyotrophic Lateral Sclerosis (ALS), chronic spinal cord injury (cSCI), and ischemic stroke. These product candidates are based on the company’s proprietary neural stem cell technology.

ADDRESS

20271 Goldenrod Lane

2nd Floor Germantown,

MD 20876

USA

WEBSITE

www.neuralstem.com

PHONE

+1 301 366 4960

COMPANY TYPE

Public

TICKER

[NASDAQ: CUR]

SECTOR

Biotechnology

YEAR FOUNDED

1996

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


MANAGEMENT TEAM

Rich Daly, President & CEO

Karl Johe, Ph.D., Chief Scietific Officer & Founder

David Recker, M.D., Chief Medical Officer

Thomas Hazel, Ph.D., Director of Research

Available at: https://investor.neuralstem.com/balance-sheet

FINANCIAL SUMMARY

PIPELINE GRAPHIC

www.sachsforum.com

NEURORX, INC.

COMPANY PROFILE

NeuroRx, Inc. is a clinical stage, small molecule pharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders. The company is built upon 30 years of basic science and clinical expertise in understanding the role of the brain’s N-methyl-D-aspartate (NMDA) receptor in regulating human thought processes in general and in regulating depression and suicidality in specific. The company’s lead drug candidate is NRX-101 (Cyclurad™), the first oral therapeutic for the treatment of Acute Suicidal Ideation/Behavior (ASIB) in Bipolar Depression.

ADDRESS

913 North Market Street

Suite 200

Wilmington, DE 19801

USA

WEBSITE

www.neurorxpharma.com

COMPANY TYPE

Private

SECTOR

Biotechnology

YEAR FOUNDED

2015

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com

NEXSTIM PLC

COMPANY PROFILE

Nexstim is a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim's NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked in Europe for the treatment of stroke, major depression and chronic neuropathic pain.

Nexstim has received clearance from the FDA for marketing and commercial distribution of its NBT® system for the treatment of Major Depressive Disorder (MDD) and looks forward to introducing the NBT® system for this important indication during H1 2018.

The NBT® system is currently in a 60 patient, supplemental Phase III study, E-FIT trial, for its use in stroke rehabilitation. The trial is expected to complete in mid-2018, allowing Nexstim to file for FDA clearance. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the USA.

ADDRESS

Elimäenkatu 9 B

FI-00510 Helsinki

Finland

WEBSITE

www.nexstim.com

EMAIL

[email protected]

PHONE

+358 9 2727 170

COMPANY TYPE

Public

TICKER

[NXTMH:FH]

SECTOR

Medical devicesDigital Health

YEAR FOUNDED

2000

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

MANAGEMENT TEAM

Martin Jamieson, CEO

Mikko Karvinen, CFO

Steve Beller, Vice President and General Manager, North America

Henri Hannula, Vice President, Sales Europe

Gustaf Järnefelt, Vice President, R&D

Hanna Kotola, Vice President Legal, Quality & Regulatory Affairs

Jarmo Laine, M.D., Vice President, Medical Affairs


www.sachsforum.com

ADDRESS

399 Bathurst Street

Suite 4W435 Toronto,

ON M5T 2S8

Canada

WEBSITE

www.nonoinc.ca

COMPANY TYPE

Private

YEAR FOUNDED

2003

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

NONO, INC.

COMPANY PROFILE


NoNO, Inc. Is on the brink of achieving one of the most ambitious goals in 21st century medicine – protecting the brain against stroke – with our lead asset NA-1 currently in two Phase 3 studies with trial sites in North America, Europe and Asia. Our scientists and physicians have been at the forefront of stroke science for two decades with an unrelenting commitment to improving life after stroke. 17 million people worldwide suffer a stroke every year – but only 10% will ever return to life as it was before. We have long believed in the promise not only of reducing ischemic damage but to unlock the brain’s own capacity to recover from disease. Our therapeutics have demonstrated potential to improve the lives of patients following ischemic stroke, traumatic brain injury, and other chronic neurological and neurodegenerative diseases.

SECTOR

Biotechnology

EMAIL

[email protected]

www.sachsforum.com

ORIGENIS GMBH

COMPANY PROFILE

ADDRESS

Am Klopferspitz 19a

82152 Martinsried

Germany

WEBSITE

www.origenis.de

EMAIL

[email protected]

PHONE

+49 89 7801676 0

COMPANY TYPE

Private

SECTOR

Biotechnology

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

Origenis is a privately-held German biopharmaceutical company developing brain-

penetrating small molecule medicines and diagnostics for a variety of

neurodegenerative and neuroinflammatory diseases.

Origenis leverages its unique capabilities in drug design, compound synthesis and

characterization to engineer a continuous stream of proprietary IP-protected new

chemical entities capable of permeating the blood-brain barrier. Origenis’ approach has

been validated by multiple partners resulting in significant IP and R&D portfolio that

ensures strong patent protection until at least 2032.

Origenis’ lead product candidates address novel but clinically-validated targets Leucine

Rich Repeat Kinase 2 (LRRK2) and Death Associated Kinase 1 (DAPK1), both of which

are associated with neurodegeneration in a variety of chronic and acute brain diseases,

including Parkinson‘s, Alzheimer’s, dementia, and traumatic brain injury, among others.

These two internal therapeutic key pipeline programs are complemented by Origenis

proprietary PET tracer programs, that enable a precision medicine approach, open new

avenues towards innovative, robust and shortened clinical development pathways with

potential for conditional approval after Phase II, and represent a diagnostic tool on its

own to enhance drug development and increase overall probability of success.

The combination of its therapeutic with the proprietary PET tracer programs not only

forms a sound basis for further clinical development, but also differentiates Origenis

from all of its competitors.

Origenis now is seeking to raise up to € 24 mill. in a Preferred Series A Equity Financing

to advance two of its internal key pipeline candidates towards IND and clinical Phase I

and is looking forward to building a transatlantic top-tier syndicate of institutional

investors both in Europe and the US.

MANAGEMENT TEAM:

Michael Almstetter, CEO

Michael Thormann, CSO

Andreas Treml, COO

Thomas Loeser, CFO

PIPELINE GRAPHIC


YEAR FOUNDED

2005

www.sachsforum.com

ORYZON GENOMICS SA

COMPANY PROFILE

ADDRESS Oryzon Corporate 245

First Street, Suite 1800

Cambridge, MA 02142

USA

WEBSITE

www.oryzon.com

EMAIL

[email protected]

PHONE

+1 617 444 8786

COMPANY TYPE

Public

TICKER

[BME: ORY]

SECTOR

Biotechnology

YEAR FOUNDED

2000

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


Oryzon Genomics – ORY (ISIN Code:ES0167733015), is a public company

headquartered in Madrid, with labs in Barcelona, Spain, and a corporate office in

Cambridge, MA, U.S. is a clinical stage biopharmaceutical company listed on MADX

since December 14th, 2015 and a European leader in the development of epigenetics-

based therapeutics.

Oryzon has a competitive Epigenetic Platform focused on developing innovative drugs

to help patients suffering from serious illnesses with strong unmet medical need such as

cancer and neurodegenerative diseases. Oryzon’s pipeline includes inhibitors against

Histone demethylases, with a strong specialization in KDM1A (LSD1) and also other

epigenetic targets.

Its oncology program ORY-1001is a selective oral LSD1 inhibitor. It has finalized a Phase

I/IIA in acute leukemia and it is currently being explored in AML and SCLC. Phase II trials

in these indications are in preparation.

The CNS program ORY-2001, a dual LSD1-MAOB inhibitor, an oral brain penetrant

compound, is in Phase II trials in relapse-remitting and progressive forms of MS

(ongoing) and in Mild to moderate AD (expected to start in 1H2018).

ORY-3001, the third epigenetic compound, also against LSD1, currently in the final stage

of preclinical development for certain orphan non-oncological diseases. Preclinical work

in SCD in monkeys and rodents has been reported in ASH-2017.

www.sachsforum.com

WEBSITEwww.palisadestherapeutics.com

COMPANY TYPE

Private

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


PALISADES THERAPEUTICS

COMPANY PROFILE

SECTOR

Biotechnology

YEAR FOUNDED

2014

MANAGEMENT TEAM:

Randice Altschul, CEO

John Gregg, COO

Neil Theise, MD, Lead Scientist

Razvan Ene, PhD, Lead Scientist - Technology

Robert Foerster, Head of New Product Planning/Forecasting

Mark Spyvee, PhD, Head of CMC/Early Development

Robert Van Heyningen, Head of New Business Development

PIPELINE GRAPHIC

Palisades Therapeutics (PT) is an entrepreneurial company with a unique operating

paradigm that is developing breakthrough neurology, psychiatric, oncology and anti-

infective compounds.

The company has more than 65 scientists, physicians, clinicians, lawyers and

professionals working together “without salary” to bring lifesaving therapeutics to the

world. The company is working in collaboration with the National Institute of Health/

National Institute of Allergy and Infectious Diseases (NIH/NIAID), the Department of

Defense (DoD) the Veterans Administration (VA) and the National Cancer Institute

(NCI).

www.sachsforum.com

WEBSITEwww.palisadestherapeutics. com

COMPANY TYPE

Private

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


SECTOR

Biotechnology

YEAR FOUNDED

2014

PIPELINE PRODUCT 3:

Autisic Spectrum Disorders

PIPELINE PRODUCT 3:

PT150

OPPORTUNITY 1:

Alcohol and Opioid Use Disorders


PT150

OPPORTUNITY 2:

Post Traumatic Stress Disorder (PTSD)


PT150

OPPORTUNITY 3:

Autisic Spectrum Disorders


PT150

PIPELINE PRODUCT 1:

Alcohol and Opioid Use Disorders

PIPELINE PRODUCT 1:

PT150 Phase 2

PIPELINE PRODUCT 2:

Post Traumatic Stress Disorder (PTSD)

PIPELINE PRODUCT 2:

PT150

www.sachsforum.com

ADDRESS

Theodor-Heuss-Str. 179

52428 Jülich

Germany

WEBSITE

www.priavoid.com

COMPANY TYPE

NFP

YEAR FOUNDED

2017

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


COMPANY PROFILEFounded on the September 18th, 2017 Priavoid GmbH is headquartered in Jülich, near Düsseldorf, Germany.

Priavoid is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS).

We develop novel therapies for the treatment of neurological diseases based on all-D-peptides. The most advanced drug in our pipeline is PRI-002, a Phase I clinical trial candidate for the treatment of Alzheimer’s disease. The treatment strategy of PRI-002 differs from conventional approaches in that the so-called „toxic oligomers“ – that is the probable cause of the neurodegenerative disease – are eliminated in the

presence of the drug candidate. The oral administration of PRI-002 leads to improvedcognitive behavior in three different transgenic mouse models.

SECTOR

Biotechnology

MANAGEMENT TEAM

Dieter Willbold

PRIAVOID GMBHSpin off from Forschungszentrum Jülich

EMAIL

[email protected]

www.sachsforum.com

PROBIODRUG AG

COMPANY PROFILE

Headquartered in Halle (Saale), Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease (AD). Probiodrug has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting a key neuro/synaptotoxic component of the pathology, pyroglutamate-Abeta (pGlu-Abeta, N3pG) as a therapeutic strategy. Its lead product, PQ912, has successfully completed a Phase 2a study. The company is also developing PBD-C06, an anti pGlu-Abeta specific monoclonal antibody. The Company has medical use and composition of matter patents related to the inhibition of QC and anti pGlu-Abeta specific monoclonal antibodies, and has, in the Company’s view, a leading position in this field of research.

Founded in 1997 by Hans-Ulrich Demuth and Konrad Glund, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Today, Probiodrug aims to become a leading company in the development of AD treatments and to thereby provide a better life for Alzheimer’s disease patients.

PIPELINE PRODUCT 1:

PQ912

PIPELINE PRODUCT 1:

About PQ912

Probiodrug’s lead product candidate PQ912, currently in Phase 2, is a highly specific and potent inhibitor of Glutaminyl Cyclase (QC), the enzyme catalyzing the formation of synaptotoxic pGlu Abeta. PQ912 has shown therapeutic effects in AD animal models. A Phase 1 study in healthy young and elderly volunteers revealed a dose dependent exposure and showed good safety and tolerability up to the highest dose with >90% target occupancy in the spinal fluid. In June 2017, Probiodrug announced top-line data of the Phase 2a SAPHIR trial of PQ912 and presented the study results at CTAD 2017. The positive effects seen on secondary exploratory efficacy markers are strongly supporting (a) the hypothesis of pGlu-Abeta being synaptotoxic and (b) the therapeutic concept pursued by Probiodrug. The study revealed a positive benefit risk ratio of PQ912 and provides important guidance how to move forward in the development of the compound as a disease-modifying drug for AD. Altogether, the results make the program highly attractive for further development; the company has initiated the preparation of a Phase 2b core program.

PIPELINE PRODUCT 2:

PBD-C06

PIPELINE PRODUCT 2:

About PBD-C06

PBD-C06, Probiodrug’s pGlu-Abeta specific monoclonal antibody, currently in preclinical stage, has the potential of being a best in class compound. The molecule is de-signed to bind aggregated pGlu-Abeta with high affinity and specificity while having, due to its specific design, a reduced potential for side effects. For the first time for an anti pGlu-Abeta approach, PBD-C06 has not only shown the ability to reduce Abeta/plaques but also to significantly improve cognitive deficits in aged Alzheimer’s mice.

ADDRESS Weinbergweg 22

06120 Halle (Saale)

Germany

WEBSITE

www.probiodrug.de

COMPANY TYPE

Public

TICKER

[AMS:PBD]

SECTOR

Biotechnology

YEAR FOUNDED

1997

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

MANAGEMENT TEAM:

Konrad Glund - Chief Executive Officer

Hendrik Liebers - Chief Financial Officer

Inge Lues - Chief Development Officer


www.sachsforum.com

PROMIS™ NEUROSCIENCES, INC.

COMPANY PROFILE

ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the TSX (ticker symbol: PMN.TO). As a development stage biotech company ProMIS’ mission is the discovery and development of best in class precision therapeutics for treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). ProMIS proprietary technology platform enables us to identify epitope targets for antibodies that are only present on the toxic oligomer “prion-like” variant of neurodgenerative proteins like TDP43, amyloid beta, SOD1, tau, and alpha-synuclein. We then validate the high selectivity of our antibodies using patient biosamples vs.controls. Our three amyloid beta antibodies in development are more selective for the toxic oligomer than late stage clincial candidates like aducanumab, which may lead to better clinical outcomes. We are actively seeking to partner our TDP4 and SOD1 programs.

ADDRESS

1920 Yonge Street

Suite 200 Toronto,

ON M4S 3E2

Canada

WEBSITE

www.promisneurosciences.

com

COMPANY TYPE

Public

TICKER

[PMN:CN]

SECTOR

Biotechnology

YEAR FOUNDED

2015

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com

SENSE DIAGNOSTICS, LLC

COMPANY PROFILE

Brain injuries, especially ones where the brain is bleeding (a brain hemorrhage), need to be diagnosed quickly. Often patients are taken to a nearby hospital that is not equipped to treat their injury and are then transferred to a trauma or stroke center. This causes delays in starting treatment that can lead to permanent disability or even death. Even after a patient gets to an appropriate hospital, additional delays occur in detecting when bleeds get worse - causing further damage. Finding a reliable, non-in-vasive way to determine if a serious brain injury is present and to monitor the injury for changes would greatly impact treatment of these patients.

Sense Diagnostics’ brain injury scanner transmits very low power radio waves (about 1/500th the power used by cell phones) through the brain. By measuring how these waves change, our scanner can tell the difference between bleeding and swelling and tell the doctor not only that there’s a problem but show them what part of the brain is involved. This information allows the doctor to make better decisions on what to do next for their patient – helping save lives, reduce disabilities and lowering the cost of treating serious brain injuries.

MANAGEMENT TEAM

Dan Kincaid, JD – CEO.

Joe Korfhagen, PhD

George Shaw, MD, PhD

Opeolu Adeoye,

Matthew Flaherty, MD

PIPELINE PRODUCT 1:

SENSE Brain Injury Scanner

PIPELINE PRODUCT 1:

The monitor has three parts. The first is a plastic headpiece that the patient wears. The headpiece houses antennas that send and receive radio signals. The second component houses the radio signal generation hardware. The other component is a computer that allows doctors to select how often to scan and set alarm limits. It also displays the information from the scans. This control unit will attach to a standard IV pole.

ADDRESS

1776 Mentor Ave. Suite 411

Cincinnati, OH 45212

USA

WEBSITE

www.senseneuro.com

EMAIL

[email protected]

PHONE

+1 844 373 6730

COMPANY TYPE

Private

SECTOR

Diagnostics

Medical Devices

YEAR FOUNDED

2014

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com

TAL MEDICAL

COMPANY PROFILE

ADDRESS

501 Boylston Street

Suite 6102,

Boston, MA 02116

USA

WEBSITE

www.talmedical.com

PHONE

+1 617 456 0032

COMPANY TYPE

Private

SECTOR

Neurotech

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


EMAIL

[email protected]

YEAR FOUNDED

2010

MANAGEMENT TEAM

Jan Skvarka, PhD, Chief Executive Officer

Steve Paul, MD, Co-founder, SAB Chair

Atul Pande, MD, Chief Financial Officer

PIPELINE

1. Pivotal study in major depressive disorder2. Confirmatory study in bipolar depression3. Pilot study in sleep/insomnia

Tal Medical is a clinical stage neuroscience company pioneering non-invasive neuromodulation treatments for brain disorders.

We aim to redefine the clinical paradigm in neuropsychiatry by introducing a safe, at-home treatment modality into mainstream clinical practice. Our lead platform, Low Field Magnetic Stimulation (LFMS), has been tested in five randomized, controlled clinical studies in depression to date.

These studies have shown rapid antidepressant effect in patients who did not respond to prior drug treatment, without any major side effects.

If our planned pivotal study confirms LFMS’ rapid antidepressant effect, LFMS could transform the way we treat depression, and become one of the most important innovations in the treatment of brain disorders.

www.sachsforum.com

TONIX PHARMACEUTICALS HOLDING CORP.

COMPANY PROFILE

Tonix is developing innovative pharmaceutical and biological products to address major public health challenges. Tonix’s lead product candidate, Tonmya, is in Phase 3 development for the treatment of PTSD at bedtime daily. TNX-601 (tianeptine oxalate) is in the pre-IND (Investigational New Drug) application stage, also for the treatment of PTSD but designed for daytime dosing. Tonix is also developing TNX-801, a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus, currently in the pre-IND application stage.

ADDRESS

509 Madison Avenue

Suite 306

New York, NY 10022

USA

WEBSITE

www.tonixpharma.com

EMAIL

investor.relations@

tonixpharma.com

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


PHONE

+1 212 980 9155

COMPANY TYPE

Public

TICKER

[NASDAQ: TNXP]

SECTOR

Biotechnology

YEAR FOUNDED

2007

www.sachsforum.com

SUPPORTING ORGANISATIONS

BIOTECHGATE

www.biotechgate.com

Biotechgate is a global, comprehensive, life science database covering the Biotech, Pharma and Medtech industries. There are currently over 36,000 company profiles on the Biotechgate database. Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com


CITIGATE DEWE ROGERSON

www.citigatedr.co.uk

Citigate Dewe Rogerson is one of the world’s leading strategic communications consultancies.

Our Life Sciences team has established a reputation for excellence spanning financial, corporate and scientific communications; this has enabled us to become trusted advisors and to build a broad portfolio including some of the most innovative and exciting international life sciences companies. Our clients are at all stages of development, from start-up to multinationals, and our activities are focused on delivering campaigns that support corporate objectives. As a result, we have been involved in major corporate transactions and events in the life sciences sector over the past de-cade such as IPOs, other public and private fundraisings, and M&As.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com


DEFINED HEALTH, A CELLO HEALTH BUSINESS

www.definedhealth.com

Defined Health is a leading business development strategy consulting firm. We’ve been assisting clients in the pharmaceutical, biotech and healthcare investment industries for more than 25 years.

Defined Health has three core lines of business, each focused on helping companies build and strengthen development-stage assets; compounds, portfolios and platforms.

A key differentiator is the firm’s focus on defining value for early stage compounds as “proof of relevance” (“PoR”), looking beyond mechanistic proof-of-concept to demonstrate clear potential for clinical differentiation and indisputable commercial value.

Defined Health’s position of trust can be leveraged for the long term, across the continuum of clinical development and “go to” market services.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com


EDISON

www.edisongroup.com

Edison is an international advisory firm with around 450 corporate clients and 110 people working from offices in London, New York, Frankfurt, Sydney and Wellington. The team consists of 80 analysts, investment and logistics professionals with experience in capital markets, investor roadshows and communications. Healthcare is Edison’s largest sector, with 16 analysts covering over 100 biotech and medtech stocks across the UK, continental Europe, North America and Asia-Pacific.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com


FREEMIND

www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist in maximizing potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind working with academics and Industry alike. FreeMind's proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date.

Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations. FreeMind's knowledgeable and experienced team of Client Strategists and Project Managers are dedicated to guiding non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist in making non-dilutive funding a key tool in a long-term financial strategy.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com


INSTINCTIF PARTNERS

www.lifesciences.instinctif.com

Instinctif Partners is an international business communications consultancy. With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities. Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copy writing, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our headquarters in London, and bases across Europe, AsiaPac and the USA.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com


SWISS BIOTECH

www.swissbiotech.org

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland’s profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies. Swiss Biotechs’ mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com


TIBEREND STRATEGIC ADVISORS, INC.

www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies:

1. To enhance valuation

2. To build visibility for partnerships and strategic alliances

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com

SACHS ASSOCIATESwww.sachsforum.com

Sachs Associates is a long established international conference company with offices in Switzerland and the UK. It runs a limited number of high profile conferences in Europe and the USA which are focused on bio-pharma, medtech, and digital health. These conferences focus on licensing and investment opportunities and all provide presenting opportunities for companies and excellent meeting facilities for all delegates to network.

Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

THE BENEFITS OF CONFERENCE PARTICIPATION WITH SACHS ASSOCIATES MAY BE SUMMARISED AS FOLLOWS:

ONLINE ONE-2-ONE MEETING SYSTEM

In order to offer the best possible provision for networking opportunities and deal making Sachs Associates provides all delegates access to our online one-to-one meeting system, allowing you to set up, accept or decline private one to one meetings with other conference attendees. These meetings last for 20 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.

CUTTING EDGE CONTENT WITH EMINENT SPEAKERS

Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Through its reputation and its long-established local relationships, the Company has attracted very senior scientific and business personalities as speakers at its events.

SPONSORSHIP AND MARKETING OPPORTUNITIES FOR FORTHCOMING EVENTS

Sachs Associates has developed an extensive knowledge of the key individuals operating within the global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase your company position in this market. Sponsorship of any of our events allows you to raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

THE FOLLOWING SPONSORSHIP AND MARKETING OPPORTUNITIES ARE AVAILABLE AT FUTURE CONFERENCES:

• Conference Sponsor – including workshops and social events

• Exhibition stands

• Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities, please call Silvia Kar on +44 203 463 4890 or email [email protected].

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S


www.sachsforum.com

EVENTS DIARY

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Silvia Kar on [email protected]

11TH ANNUALEUROPEAN LIFE SCIENCES CEO FORUM & EXHIBITION

FOR PARTNERING AND INVESTING IN BIOTECH & PHARMA INDUSTRY

26TH – 27TH FEBRUARY 2018 • HILTON ZURICH AIRPORT HOTEL • SWITZERLAND

Back for its eleventh year, this exclusive and highly transactional partnering event is a must for companies wishing to meet with their peers, engage with leading investors and forge new partnerships.

Building on the success of this year’s event, the forum will provide an excellent platform to gain insight into partnering and investment trends in the Biotech and Pharma industry. Networking at the forum is facilitated by our online One-2-One meeting system, which is available to all participants.

The conference will feature up to 80 presentations by large to mid-size pharmaceutical companies looking for strategic alliances/partners, plus 20+ short presentations by seed companies.

Do not miss out on this great opportunity to meet emerging companies, leading global investors and Big Pharma representatives!

SACHS BIOCAPITAL USA FORUM

FOR PHARMA – BIOTECH PARTNERING & INVESTMENT OPPORTUNITIES

21ST MARCH 2018 • NEW YORK ACADEMY OF SCIENCES • USA

Returning to New York in March 2018, Sachs Associates is pleased to announce the Sachs BioCapital USA Forum. Building on the success of Sachs Forums in Europe and the USA, we decided to combine the 2nd Neuroscience BioPartnering & Investment and the 5th Cancer BioPartnering & Investment forums and make one event - Sachs BioCapital USA Forum (BCUSA) that will take place on the 21st of March at the at the New York Academy of science.

The BCUSA showcases biotechs with advanced therapeutics and brings them together with pharma partnering executives and institutional investors, bankers and advisers. The programme features panels on pharma-biotech dealmaking, advances in different therapeutics areas and a keynote and roundtable on investment. We anticipate up to 300 delegates and around 30 company presentations (public and private) and an emerging company track. Our online One-2-One meeting system with dedicated meeting facilities will provide numerous networking opportunities and will make event even more transactional.

4TH ANNUALIMMUNO-ONCOLOGY: BD&L & INVESTMENT FORUM1ST JUNE 2018 • WALDORF ASTORIA CHICAGO HOTEL • USA

Taking place on the first day of ASCO, the 4th Annual Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment.

Numerous networking opportunities available via an online one-to-one meeting system with dedicated meeting facilities to make the event more transactional.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

www.sachsforum.com


WE

LC

OM

EO

RG

AN

ISE

RS

www.sachsforum.com

6TH ANNUALMEDTECH & DIGITAL HEALTH FORUM

3RD OCTOBER 2018 • CONGRESS CENTER BASEL • SWITZERLAND

This year again we will be holding our 6th MT&DH Forum one day before our 18th Annual BEF Forum, on 3rd of October at the Congress Center Basel. The programme is designed to highlight the latest industry developments and showcase emerging and innovative technology companies seeking finance and partnerships. The delegates are comprised of Healthcare, MedTech, Healthcare IT and Digital Health companies as well as consultants, bankers and corporate & financial investors. We expect over 250 delegates and 25 presenting companies plus presentations by seed companies.

The forum will provide a number of networking opportunities via our online one-to-one meeting system which allows you to pre-book meetings with all the attendees with dedicated meeting facilities.

18TH ANNUALBIOTECH IN EUROPE FORUM4TH – 5TH OCTOBER 2018 • CONGRESS CENTER BASEL • SWITZERLAND

The forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. We expect over 650 delegates and over 100 presenting companies plus presentations by seed companies.

The 18th Annual BEF will be held for the fifth time in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand one-to-one meetings as well as significant exhibition space. The programme will feature number of plenary panels/workshops covering BD & Licensing in the main therapeutic areas.

The forum will provide a number of networking opportunities via our online one-to-one meeting system which allows you to pre-book meetings with all the attendees with dedicated meeting facilities. We expect more than 1500 meetings to take place throughout the 2 days.

WE

LC

OM

ES

PE

AK

ER

SP

RE

SE

NT

ING

CO

MPA

NIE

SS

UP

PO

RT

ING

O

RG

AN

ISA

TIO

NS

OR

GA

NIS

ER

S

www.sachsforum.com


WE

LC

OM

EO

RG

AN

ISE

RS

www.sachsforum.com

neuroscience speakers innovation forum · 2018/10/05 · neuroscience innovation forum for...

Documents